Exploring the relationship between impaired awareness of hypoglycaemia and autonomic neuropathy in type one diabetes mellitus. by Walkinshaw, EMMA





Impaired Awareness of 
Hypoglycaemia and 
Autonomic 
Neuropathy in Type 
One Diabetes Mellitus.  
 
 
 Emma Walkinshaw                                                                                                                           
A thesis submitted in partial fulfilment of the requirements for the degree of 




The University of Sheffield 













































Background: Severe hypoglycaemia is a much feared complication of type one 
diabetes mellitus (T1DM) and historically diabetic autonomic neuropathy (DAN) 
was described as the underlying mechanism.  The aim of these studies was to 
clarify if there is a relationship between DAN and impaired awareness of 
hypoglycaemia (IAH), the role DAN has in preventing improvement in IAH and 
cardiac autonomic response to hypoglycaemia.  
Methods: Participants with T1DM and IAH (Gold score ≥4), and participants 
with T1DM and normal awareness of hypoglycaemia (Gold score <4) were 
recruited.  They underwent cardiac autonomic function testing and were invited to 
undergo a stepped hyperinsulinaemic hypoglycaemic clamp study.  The 
participants with IAH underwent a treatment programme aimed at improving 
awareness of hypoglycaemia. 
Results: The prevalence of DAN and IAH was associated with a longer duration 
of disease.  Awareness of hypoglycaemia improved in all patient groups (mean 
improvement Gold score ≥1) independent of cardiac autonomic function status but 
younger participants and those with a shorter duration of disease showed greater 
improvements.  During hypoglycaemic clamp studies baseline heart rate was 
higher and vagal tone lower, in participants with diabetes compared to participants 
without diabetes.  During hypoglycaemia heart rate increased with vagal 
withdrawal in participants with T1DM and normal awareness of hypoglycaemia.  
Little change in heart rate or heart rate variability was seen in participants with 
IAH.   
Conclusions: The presence of cardiac autonomic neuropathy is not associated 
with IAH.  Heart rate response to hypoglycaemia was time dependent and differed 
according to self reported awareness of hypoglycaemia.  We suspect this is due to 
a failure of autonomic responses to hypoglycaemia associated with long duration 
of disease and reduced autonomic responses following repeated episodes of 
hypoglycaemia.  Future work would be aimed at epidemiological studies to 
document an accurate prevalence of DAN and examining the possible associations 
with other complications of diabetes.    
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Chapter 1: Background 
1.1 Type One Diabetes Mellitus 
Diabetes mellitus is a disorder of glucose metabolism that leads to high blood 
glucose levels (hyperglycaemia).  There are two main types; type one (T1DM) 
and type two (T2DM).  T1DM usually presents in childhood or adolescence and is 
an autoimmune condition.  Destruction of the insulin producing beta cells of the 
pancreas results in insulin deficiency and hyperglycaemia.  
 
T1DM is treated with subcutaneous insulin either via injection or by continuous 
infusion.  Intensive insulin therapy is a term used to describe the tight 
management of blood glucose levels with the aim of avoiding the long term 
complications of diabetes (Group, 1993).  It involves multiple daily injections of 
insulin, regular blood glucose testing and carbohydrate counting to calculate 
insulin doses.    
 
The aim of intensive insulin therapy in T1DM is to mimic physiological 
endogenous insulin release.  When blood glucose levels rise, the beta cells of the 
pancreas are stimulated to release insulin.  The insulin is secreted into the portal 
vein, which enters the liver.  Endogenous glucose production is inhibited and 
there is significant portal extraction of insulin before the blood enters the systemic 
circulation (Song et al., 2000). 
The limiting factor in subcutaneous insulin delivery is the systemic utilisation of 
insulin before hepatic extraction.  ‘The periphery is over insulinised and the liver 
is underinsulinised’ (Russell-Jones and Khan, 2006).  This leads to a 
disproportionate systemic effect of insulin with increased peripheral glucose 
utilisation, a reduction in lipolysis and reduced hepatic glucose production 
suppression.     
The clinical effects of over insulinisation are weight gain and hypoglycaemia.  
Despite the advances made in insulin formulations and delivery, subcutaneous 
insulin does not match the physiological response of the pancreatic beta cells.  As 
a consequence, when aiming for normal blood glucose (normoglycaemia), there is 
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at times, an excess of insulin within the blood stream, which can cause low blood 
glucose (hypoglycaemia).  
Hypoglycaemia is the main limiting factor preventing good glycaemic control in 
T1DM.  It is a major cause of physical and psychological morbidity and can in 
rare cases be fatal (Cryer et al., 2003).  The Diabetes Control and Complications 
Trial (DCCT) showed that intensive insulin therapy leads to an increase in 
episodes of severe hypoglycaemia (SH) (Group, 1991) (Figure 1).  If it were not 
for hypoglycaemia patients could aim for tight management of blood glucose 
levels without concern (Cryer, 2002).  
 
 




“The  price of normoglycaemia is often hypoglycaemia” (Hillson, 2008). 
Hypoglycaemia is a recognised side effect of treatment with insulin.  It was first 
described by Banting et al (Banting et al., 1923) during his early work regarding 
insulin administration in diabetes.  Early symptoms of hunger, tremor, sweating 
and pallor were followed by confusion and disorientation and finally coma.  The 











episodes of SH 
Treatment groups 
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Hypoglycaemia in T1DM is common.  Patients report mild (self-treated) episodes 
occurring once to twice a week (Leese et al., 2003).  Severe episodes (defined as 
an episode requiring assistance from another person) affect 30% of patients with 
T1DM and occur on average once a year (Leese et al., 2003) (Cryer et al., 2003).  
Nocturnal hypoglycaemia is also common and often asymptomatic (Beregszaszi 
et al., 1997) (Kaufman et al., 2002).  The incidence of nocturnal hypoglycaemia in 
young patients with T1DM has been reported to be as high as 47%  with almost 
half being asymptomatic (Beregszaszi et al., 1997).    
Hypoglycaemia affects all aspects of life in a patient with T1DM (Leelarathna et 
al., 2013) including employment and leisure time.  Alongside the physical effects, 
psychological effects include anxiety and fear of hypoglycaemia (Cryer et al., 
2003).  Episodes of SH are associated with an increased risk of death with a 
reported 3.4 fold increased risk at five years (McCoy et al., 2012) 
1.2.1 Glucose Counterregulation 
Glucose counterregulation is the normal physiological response that prevents and 
corrects hypoglycaemia.  In an individual without diabetes, endogenous insulin 
secretion is reduced and then completely inhibited as blood glucose levels 
decrease (Cryer, 2002) preventing hypoglycaemia from occurring (McAulay et 
al., 2001).    In experimental studies where insulin is given to induce 
hypoglycaemia, the counterregulatory hormones glucagon, adrenaline, growth 
hormone and cortisol are released.  This stimulates the liver to produce glucose 
and reduce utilisation by the peripheral tissues.  The release of the 
counterregulatory hormones occurs before the individual experiences any 
symptoms (Schwartz et al., 1987) (Figure 2).    
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Figure 2 As plasma glucose is reduced insulin secretion is reduced and glucagon and adrenaline are 
released before the occurrence of symptoms (Adapted from (Cryer et al., 2003)).  
Symptoms of hypoglycaemia are divided into two groups; autonomic symptoms 
and neuroglycopenic symptoms (McAulay et al., 2001).  Autonomic warning 
symptoms of hypoglycaemia include palpitations, sweating, tremor and hunger.  
They are mediated by the autonomic nervous system and are thought to be mainly 
a result of sympathoadrenal activation and the release of noradrenaline, adrenaline 
and acetylcholine (McAulay et al., 2001) (Cryer et al., 2003). The 
neuroglycopenic or cognitive symptoms of hypoglycaemia include confusion, 
poor concentration, blurred vision and, more rarely, seizures and coma.  They 
usually occur at lower blood glucose levels than the autonomic symptoms 
(Mitrakou et al., 1991) and are caused by a lack of glucose available for utilisation 
in the brain.   
1.2.2 Glucose Counterregulation in T1DM 
Normal glucose counterregulation is impaired in T1DM patients.  Firstly, the 
exogenous insulin used to treat T1DM, is injected into the subcutaneous tissues, 
and will continue to be absorbed irrespective of blood glucose levels (Cryer, 
2001).  The second line of defence is the release of glucagon which stimulates the 
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release of glucose from the liver.  This response has been shown to be blunted in 
comparison to adults without diabetes (Bolli et al., 1982) after five years of 
treatment of T1DM.  As these first two defences against hypoglycaemia are 
impaired in T1DM, adrenaline release becomes increasingly important.  Growth 
hormone and cortisol levels also increase in hypoglycaemia but they seem to play 
a minor role in glucose counterregulation (Cryer, 2002).   
 
T1DM patients often have an attenuated adrenaline response to hypoglycaemia.  
Amiel et al (Amiel et al., 1988) showed that after a period of intensified insulin 
therapy, with improved glycaemic control and a reduction in HbA1c, patients 
required a lower blood glucose level to stimulate adrenaline release.  The 
concentration of adrenaline produced was also lower and symptom awareness of 
hypoglycaemia was reduced.   
 
1.2.3. Antecedent hypoglycaemia reduces awareness of subsequent episodes 
A previous episode of hypoglycaemia will reduce both plasma adrenaline and 
symptomatic responses to future episodes.  Heller and Cryer (Heller and Cryer, 
1991) studied nine subjects without diabetes that underwent morning 
hypoglycaemic (glucose 2.8 mmol/l) clamp studies following afternoon 
hypoglycaemia (glucose 3mmol/l) and afternoon euglycaemia (5mmol/l).  Plasma 
adrenaline, glucagon, cortisol and symptomatic responses in the hypoglycaemic 
clamp studies were reduced after a single episode of afternoon hypoglycaemia.  
This was confirmed by a similar study by Dagogo-Jack et al in patients with 

















0 14 13 5.6 
60 16 15 5.0 
120 18 15 4.4 
180 19 18 3.9 
240 22 19 3.3 
300 42 22 2.8 
Table 1: Total symptom score in response to morning hypoglycaemia following either afternoon 
hyperglycaemia or hypoglycaemia (Adapted from (Dagogo-Jack et al., 1993)). 
 
The term ‘Hypoglycaemia Associated Autonomic Failure’, or HAAF, is used by 
some groups to describe the reduction in adrenaline release and symptoms to 
hypoglycaemia following a previous episode (Dagogo-Jack et al., 1993) (Vinik et 
al., 2003).  HAAF reduces the defence against hypoglycaemia, leading to further 
episodes, which then result in further reductions in symptomatic and hormonal 
response to low blood glucose levels.  This cycle of repeated hypoglycaemia 
reducing the defence against further episodes is particularly common in patients 
with tight glycaemic control (Vinik et al., 2003). 
 
The term HAAF can be misinterpreted to suggest that classical diabetic autonomic 
neuropathy (DAN) is the underlying cause.  Classical DAN is a complication of 
diabetes.  The pathogenesis is still unclear but it has been shown to be a structural 
disorder with degenerative changes of the distal axons and nerve terminals  
(R.E.Schmidt, 2002) (Adamson  et al., 1984).  DAN is mostly irreversible; some 
improvement has been shown in mild cases with improved glycaemic control but 
treatment is mainly aimed at symptomatic relief if advanced (Vinik et al., 2003).  
The mechanism underlying HAAF is also unclear.  It occurs after one episode of 
hypoglycaemia in both subjects with and without diabetes and can be reversed by 
complete avoidance of hypoglycaemia.  This suggests a functional disorder rather 
than a structural one.  
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           Absolute Insulin Deficiency 
 
              T1DM 
 
              Imperfect Insulin Replacement 
 
Impaired Awareness        HYPOGLYCAEMIA         Defective  
Hypoglycaemia                                                           Glucose 
                                                                        Counteregulation 
 
                 Reduced Autonomic Responses 
 
Reduced Symptomatic                                                Reduced      
Response                                                        Adrenaline                                                     
Figure 3: HAAF.  Recent antecedent hypoglycaemia reduces adrenaline release and symptomatic 
awareness of further episodes of hypoglycaemia (Adapted from (Cryer, 2002)).  
 
Dagogo-Jack et al (Dagogo-Jack et al., 1993) showed that in subjects, with and 
without DAN, lower glucose levels were required to elicit symptomatic responses 
to morning hypoglycaemia following afternoon hypoglycaemia compared to 
afternoon hyperglycaemia.   Twenty six participants were recruited including 11 
patients with DAN.  Adrenaline levels were also significantly lower (P=0.0060) in 
response to hypoglycaemia following afternoon hypoglycaemia in participants 
with diabetes.  The group found that adrenaline responses to hypoglycaemia did 
not differ in participants with and without DAN.   
 
Although DAN and HAAF are separate entities other groups have challenged the 
findings by Dagogo-Jack and colleagues.  It has been reported by several groups 
that a further reduction in adrenaline secretion is seen in patients with DAN 
compared to patients without neuropathy (Hilsted et al., 1981) (Bottini et al., 
1997) (Polinsky et al., 1980, Hoeldtke et al., 1982).  Patients in the Dagogo-Jack 
study (Dagogo-Jack et al., 1993) were diagnosed with DAN on the basis of one 
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abnormal test and self reported symptoms.  Recommendations now state that 
definite DAN should only be diagnosed in those patients with two or more 
abnormal tests (O'Brien et al., 1991).  This may explain the discrepancy between 
studies.   
 
1.2.4 Impaired Awareness of Hypoglycaemia  
Impaired awareness of hypoglycaemia (IAH) refers to the absence of the early, 
autonomic, warning symptoms of hypoglycaemia before neuroglycopenia occurs 
(Boyle et al., 1995) and is associated with an increased risk of SH (Gold et al., 
1994).  A prospective study carried out by Gold et al (Gold et al., 1994) showed 
that patients with IAH had an average annual incidence of severe hypoglycaemia 
of 2.8 compared to 0.5 episodes per year in patients with normal symptomatic 
responses to hypoglycaemia.  Patients were clinically divided into two groups; 
those with reversible unawareness related to tight glycaemic control and those 
with irreversible unawareness related to a long duration of disease (Gold et al., 
1994).   
Experimental studies indicate that IAH is a result of an abnormal response of the 
sympathoadrenal system.  Berlin et al (Berlin et al., 1987) challenged this by 
showing that in patients with reduced symptomatic awareness of hypoglycaemia 
there was also a reduced sensitivity to Isoproterenol, a Beta-adrenergic agonist.  
However, catecholamines (adrenaline and noradrenaline) were not measured 
during the Isoproterenol sensitivity test and Hilsted et al (Hilsted et al., 1987) 
have showed a normal response to adrenaline infusions in patients with diabetes.  
Other studies have consistently shown a reduction in adrenaline levels in response 
to experimental hypoglycaemia in patients with IAH (Heller et al., 1987, 
Adamson  et al., 1984). 
 
IAH is a well established phenomenon (Lawrence, 1941) and has a prevalence of 
25% in patients with T1DM (Geddes et al., 2007).  Studies regarding IAH are 
difficult to interpret due to numerous confounding factors including duration of 
diabetes, glycaemic control and HbA1c  (Mokan et al., 1994).  Hepburn et al. 
(Hepburn et al., 1990) studied a group of 226 patients with insulin dependent 
diabetes selected at random from a clinic in Edinburgh.  Forty eight (16%) 
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patients reported partial awareness and twenty one patients (7%) had absent 
awareness of hypoglycaemia.  The group with absent awareness was divided by 
duration of diabetes and only four patients (19%) had diabetes of less than 15 
years duration.   
The relationship between IAH, duration of diabetes and tight glycaemic control 
was corroborated by a study by Mokan et al (Mokan et al., 1994).  They studied 
43 patients with T1DM.  Patients were admitted for a hypoglycaemic clamp study 
in which plasma glucose was clamped at 4.3, 3.6, 3.0 and 2.3 mmol/l.  Patients 
completed symptom questionnaires every 15 minutes and underwent cognitive 
testing at each glucose plateau.  Eleven patients (26%) were classified as having 
IAH which was defined as the development of autonomic symptoms at plasma 
glucose levels more than 2 SD below normal.  Those patients with IAH had a 
longer duration of diabetes and a lower HbA1c (Table 2). 
 
 IAH P values 
Duration of diabetes <10 years 











Duration >10 years and HbA1c <9% 





Table 2 Effect of duration of diabetes and HbA1c on frequency of IAH (Adapted from (Mokan et al., 
1994)). 
Impaired adrenergic and symptomatic responses to hypoglycaemia are common in 
patients with T1DM with established disease even in those who claim to have 
normal awareness of hypoglycaemia (Heller et al., 1987) (Olsen et al., 2014).  
Heller et al (Heller et al., 1987)found that only 4/15 subjects with diabetes 
recognised hypoglycaemia of 2.5mmol/l during a hypoglycaemic clamp study 
despite 10/15 subjects claiming to have intact awareness.  They also established 
that adrenaline secretion was more pronounced in subjects without diabetes and 
the 4/15 subjects with diabetes that recognised hypoglycaemia from their 
symptoms.  Olson et al (Olsen et al., 2014) found that subjective symptoms of 
hypoglycaemia change over time.  Participants reported a lower intensity of 
July 2018 Page 23 
 
autonomic symptoms of hypoglycaemia as duration of diabetes increased and the 
mean neuroglycopenic/autonomic symptom ratio increased.    
IAH can potentially be reversed.  A group of patients with insulinomas (insulin 
secreting tumour) and frequent hypoglycaemia showed reduced symptomatic and 
counterregulatory responses to hypoglycaemia.  This recovered following surgical 
cure (Mitrakou et al., 1993).  Some recovery of symptomatic and adrenaline 
response to hypoglycaemia is also seen in T1DM patients following meticulous 
avoidance of low blood glucose levels (Fanelli et al., 1993a) (Cranston et al., 
1994).  However, patients with a longer duration of diabetes only showed a partial 
recovery of adrenaline response (Fannelli et al., 1994).  This may explain the 
conflicting findings in a further study by Dagogo-Jack and colleagues that studied 
a small number of patients with a long duration of diabetes (Dagogo-Jack et al., 
1994).   
 
Treatment of IAH requires complete avoidance of hypoglycaemia (Zoysa et al., 
2013).  To achieve this patients undergo time consuming and expensive 
educational treatment programmes (Zoysa et al., 2013).  Ideally patients that will 
not or will only partially respond to these treatment programmes would be 
identified to allow these resources to be used appropriately.  
 
1.2.5 Summary 
Hypoglycaemia prevents good glycaemic control in T1DM.  Patients are 
vulnerable because of imperfect insulin replacement, the need for tight glycaemic 
control and impaired counterregulatory responses.  Warning symptoms of a low 
blood glucose reduce after a single episode of hypoglycaemia and change with 
increased duration of disease.  This increases the risk of SH although patients are 
often unaware of their diminished symptomatology. 
 
IAH is a clinical entity where the autonomic symptoms of hypoglycaemia are 
reduced or absent increasing the risk of neuroglycopenia and SH.  It is more 
prevalent in patients with a long duration of disease and those with tight 
glycaemic control.  Traditionally it has been thought to be due to DAN but this is 
a structural, irreversible complication of diabetes where IAH is a functional and 
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reversible disorder.  Treatment of IAH is expensive due to the requirement of 
intensive support from skilled and specially trained medical staff.  Despite this, 
there are a proportion of patients who will not respond to treatment but currently 
these patients can’t be identified before commencing treatment. 
1.3 Diabetic Autonomic Neuropathy 
‘DAN is among the least known and understood complications of diabetes’(Vinik 
et al., 2003).  It is a peripheral neuropathy that affects the autonomic nervous 
system, in patients with diabetes, after exclusion of other causes (Tesfaye et al., 
2010).  It can manifest with abnormalities in the cardiovascular, gastrointestinal, 
genitourinary, sudomotor or ocular systems (Consensus, 1988) and can be a 
clinical or subclinical finding (Vinik et al., 2003).   
 
The reported prevalence of DAN in patients with T1DM ranges between 0 to 90% 
depending upon the group of patients investigated and the diagnostic criteria used 
(Vinik et al., 2003).  The pathogenesis of DAN is unclear and hypotheses include 
vascular disease, hyperglycaemia and autoimmune dysfunction (Vinik et al., 
2003) (Clarke et al., 1979).  There is an increased risk for patients with a longer 
duration of diabetes (Dyrberg et al., 1981), increasing age (Boulton et al., 2005) 
and poor glycaemic control (Group, 1993).   
 
Cardiac autonomic dysfunction is the most studied subgroup of the autonomic 
neuropathies (Boulton et al., 2005) because of the association with an increased 
risk of death (O'Brien et al., 1991).  The diagnosis is made by examining changes 
in blood pressure and heart rate variability (HRV) at rest and during different 
manoeuvres.  The tests are simple, non-invasive and can be completed at the 
bedside (Fisher, 2002).    
Prognosis of DAN is poor and, once established, mostly irreversible.  Ewing et al. 
(Ewing et al., 1980) studied a population of 73 participants with diabetes 
participants.  Forty had abnormal cardiac autonomic function tests (AFTs) of 
which 21 (53%) died in comparison with 5 (15%) in the group of 33 patients with 
normal tests. Repeat testing during the five year follow up period showed that 
some tests that were normal became abnormal but abnormal tests did not 
normalise.  A later review by Vinik and Ziegler (Vinik and Ziegler, 2007) did 
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report the potential to improve heart rate variability (HRV) in patients with 
minimal abnormalities.  Regular exercise can improve HRV in patients with 
diabetes with no or early DAN (Howorka et al., 1997) and some improvement has 
also been seen with the use of angiotensin converting enzyme inhibition and 
angiotension receptor blockade (Didangelos et al., 2006). 
 
The clinical symptoms of DAN are varied (Freeman, 2005) and depend upon the 
organ affected.  Clinically, cardiac autonomic neuropathy, can cause a resting 
tachycardia and postural hypotension (Boulton et al., 2005) as the condition 
progresses.  Traditionally DAN has been described as the underlying cause of 
IAH.  This is because adrenaline release seen in response to hypoglycaemia is a 
function of the autonomic nervous system and adrenaline release is attenuated in 
DAN (Hilsted et al., 1981) (Bottini et al., 1997) (Polinsky et al., 1980, Hoeldtke et 
al., 1982) but the evidence in the literature is limited and contradictory.   
 
The EURODIAB IDDM Complications Study (Stephenson et al., 1996) reported 
that DAN increases the risk for severe hypoglycaemia in T1DM.  3248 patients 
with insulin dependent diabetes were recruited and 1046 (32%) reported an 
episode of severe hypoglycaemia in the year prior to recruitment to the study.  
Cardiac autonomic function was assessed by measuring HRV and blood pressure 
response to standing.  In those patients that reported severe hypoglycaemia 126 
(13%) were diagnosed with autonomic neuropathy compared to 157 (8%) without 
episodes of severe hypoglycaemia ((p=0.002), unpaired t test).  This was a large 
study but only two measures of autonomic function were undertaken in 
comparison to the standard five tests usually completed risking under diagnosis of 
neuropathy.  The study also relied upon patients to report episodes of severe 
hypoglycaemia rather than measuring response to experimental hypoglycaemia.   
 
Meyer and colleagues (Meyer et al., 1998) explored the claim that DAN was an 
independent risk factor for severe hypoglycaemia with a study published in 1998.  
Twenty two participants with T1DM, including eight with autonomic neuropathy, 
were recruited with thirty three participants without diabetes.  All participants 
underwent a stepwise hypoglycaemic clamp.  The threshold for the release of 
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adrenaline was higher (required a lower blood glucose) and levels of adrenaline 
lower in participants with diabetes.  The impairment of adrenaline release was 
further attenuated in the participants with autonomic neuropathy.   The reduction 
in adrenaline response to hypoglycaemia in patients with DAN has been well 
documented in other studies (Bottini et al., 1997) (Polinsky et al., 1980) (Hoeldtke 
et al., 1982) although duration of diabetes, a well established confounding factor, 
is not always controlled for. 
 
In their analysis, Meyer and colleagues found that symptomatic responses to 
hypoglycaemia correlated with the magnitude of adrenaline released in the 
participants without diabetes but not among the participants with diabetes.  They 
compared responses in the thirty three participants without diabetes, four patients 
with diabetes with DAN and five patients with diabetes and normal autonomic 
function.  The lack of correlation in the populations with diabetes may be due to 
the small number of participants included in the analysis. 
 
Ryder and colleagues (Ryder et al., 1990) reported a lack of correlation between 
symptomatic awareness of hypoglycaemia and the presence or absence of DAN in 
1990.  They hypothesized that if there is an association between DAN and IAH 
then patients with autonomic neuropathy will have IAH and patients with poor 
warning symptoms for hypoglycaemia will have autonomic neuropathy.  To 
examine this hypothesis they studied four groups of patients; seven T1DM 
patients with symptomatic autonomic neuropathy, nine T1DM patients with 
frequent episodes of severe hypoglycaemia, seven T1DM patients without the 
concerns of the first two groups and ten healthy controls.  A thorough assessment 
of autonomic function was completed followed by an insulin infusion to assess the 
counterregulatory response to hypoglycaemia.  An inadequate response to 
hypoglycaemia was defined as neurological manifestations of hypoglycaemia or a 
blood glucose that dropped to below 1.9mmol/l.  Counterregulatory hormones 
were not measured.   
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Of the seven patients with DAN there were no patients with an inadequate 
response to hypoglycaemia and of the seven patients with an inadequate response 
to hypoglycaemia none had autonomic neuropathy.  Ryder et al (Ryder et al., 
1990) reported that there was no association between unawareness of 
hypoglycaemia and DAN.  However, the validity of their conclusions is 
threatened by the small number of participants recruited and lack of measurement 
of catecholamines. 
 
Hepburn et al (Hepburn et al., 1990) supported the hypothesis made by Ryder and 
colleagues (Ryder et al., 1990) that IAH is not invariably associated with 
autonomic dysfunction.  They studied 306 insulin dependent diabetics.  Twenty 
one (7%) patients reported absence of symptomatic awareness of hypoglycaemia.  
AFTs were carried out on 226 patients and eighty five (38%) had abnormal tests.  
Sixty two (37%) patients with normal awareness had abnormal AFTs compared 
with 14 (67%) in the absent awareness group.  The groups were then analysed 
depending on duration of diabetes.  For patients that had had diabetes for more 
than 15 years, thirty nine (54%) with normal awareness had abnormal autonomic 
function tests compared to ten (59%) in the absent awareness group.  They 
concluded that ‘the precise relationship between DAN and loss of hypoglycaemia 
awareness remains undefined’ 
 
Studies investigating reversibility of IAH usually exclude patients with DAN to 
rule out its potential impact on the response to treatment.  Fanelli and colleagues 
(Fanelli et al., 1997) recruited 21 patients with IDDM with a history of  recurrent 
hypoglycaemia without warning symptoms and 15 subjects without diabetes. 
Thirteen of the participants with diabetes had DAN and eight had normal 
autonomic function tests.   Participants with autonomic neuropathy were older but 
the long duration of diabetes and HbA1c levels were comparable between the 
groups.  The participants underwent a stepped hypoglycaemic clamp before and 
after 6 months of meticulous avoidance of hypoglycaemia.  After 6 months of 
hypoglycaemia avoidance all patients with diabetes had an improvement in 
autonomic symptoms and adrenaline response to a low blood glucose but the 
improvement was lower in participants with DAN than those with normal 
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autonomic function.  This suggests that DAN does impede the reversal of 
hypoglycaemia unawareness to a degree. 
 
Interestingly the participants with diabetes did not improve their symptomatic and 
adrenaline responses to hypoglycaemia to the level of the subjects without 
diabetes (Figure 4) confirming the findings in other studies with patients with a 
long duration of diabetes.  This conflicts with the complete recovery from 
hypoglycaemia unawareness seen in patients with a short duration of T1DM.  It 
may be that patients with a long duration of diabetes have a degree of autonomic 
neuropathy that cannot be detected clinically, that causes a lack of complete 
recovery of IAH.  Or a long duration of disease could cause structural changes, 




Figure 4 Maximal adrenaline responses to hypoglycaemia in subjects without diabetes, patients with 
diabetes without autonomic neuropathy (DAN-) and those with autonomic neuropathy (DAN+) (Adapted 
from Fanelli et al (Fanelli et al., 1997)). 
 
In summary exploring the contribution of DAN alone to IAH is challenging.  
Patients with established DAN have longstanding diabetes which confounds 
investigation.  Currently there are no studies in the literature that have measured 
the responses of DAN affected patients to hypoglycaemia while controlling for 

















End of study 
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1.4 T1DM and the Heart 
1.4.1 Pathophysiology of Hypoglycaemia 
Acute hypoglycaemia stimulates the sympathetic nervous system with the release 
of catecholamines (Schwartz et al., 1987).  This is crucial in T1DM as the first 
two mechanisms of defence, reduction in circulating insulin and glucagon release, 
are impaired.  Activation of  sympathetic nervous system has a well documented 
effect on the cardiovascular system which includes an increase in heart rate and 
cardiac output (Triposkiadis et al., 2009). 
 
Experimental hypoglycaemia has been shown to cause an increase in heart rate, 
blood pressure and cardiac output (Hilsted et al., 1984) (Fisher et al., 1987) 
(Fisher et al., 1990).  The effects of hypoglycaemia on the cardiovascular system 
are a direct effect of the increase in heart rate.  Some of these effects are due to the 
direct neural sympathetic innervations to the heart, rather than to 
counterregulatory hormonal response, as maximal heart rate has been shown to 
precede maximal catecholamine rise (Fisher et al., 1987).  
 
The cardiovascular response in participants with diabetes has been shown to be 
slower and blunted in comparison to the people without diabetes (Russell et al., 
2001).  This coincides with a blunted catecholamine response to hypoglycaemia in 
subjects with diabetes.  The cardiovascular parameters also change during 
hyperinsulinaemic euglycaemia but to a lesser extent than during hypoglycaemia. 
 
Hyperinsulinaemic hypoglycaemia is associated with specific and well 
documented ECG changes.  Studies have shown that prolonged cardiac 
repolarisation or heart rate corrected QT interval (QTc) occurs during 
hypoglycaemia (Laitinen et al., 2003, Marques et al., 1997).  The mechanism is 
thought to be due to a combination of adrenaline and hypokalaemia (Robinson et 
al., 2003a).  This effect is seen in spontaneous hypoglycaemia, although to a 
lesser degree, as well as in experimental clamp studies (Christensen et al., 2014).       
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1.4.2 Hypoglycaemia Associated Mortality  
Intensive treatment of T1DM improves glycaemic control and prevents the long 
term complications of diabetes (Group, 1993).  In the DCCT patients in the 
intensive treatment arm had delayed onset of diabetic retinopathy, nephropathy 
and neuropathy (Group, 1993).  The delay in complications was sustained for at 
least 8 years despite a deterioration in glycaemic control once the trial had 
finished (Study, 2003).    
 
However, despite this, concern has been raised that intensive treatment of diabetes 
could be linked to an increase in mortality (Group, 2008).  The intensive treatment 
arm of the ACCORD study, a randomised controlled trial, to assess the effect of 
intensive glycaemic management versus standard therapy on cardiovascular 
events, had to be prematurely stopped due to high mortality rates.  Of the 
participants in the intensive treatment group 1.42% of patients died each year 
compared to 1.14% in the standard treatment arm (HR 1.22 CI 1.01 to 1.46 
P=0.04)  (Bonds et al., 2010).   
 
It was initially suggested that this increase in mortality was related to 
hypoglycaemia.  Participants that had experienced an episode of SH were at an 
increased risk of death.  Further analysis, however, showed that this increased risk 
was regardless of which treatment arm the participant was in (Table 3 p=0.009).  
Also, the increased risk of death in the intensive treatment group could not be 
solely attributed to SH as the risk of death was lower in the intensive arm of the 
study than in the standard arm in participants that had experienced an episode of 
SH (HR 0.55, 95% CI 0.31-0.99).  Other studies confirm that episodes of SH are 
an independent risk factor for death (Duckworth et al., 2009) (Zoungas et al., 
2010) but the link is not direct and it is unclear if hypoglycaemia is a result of or 
contributing factor of vulnerability to morbidity and mortality. 
 
A recent meta analysis by Goto et al (Goto et al., 2013) concluded that SH was 
associated with increased cardiovascular death.  The risk of cardiovascular disease 
was found to double in those patients experiencing SH.  A bias analysis found the 
presence of co-morbidities could not explain this increased risk.  
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Treatment Arm Zero episodes of 
SH requiring 
medical assistance 
At least one 




for no previous 
events vs. at 
least one event 
(95% CI) 
Intensive 1.3% 
220 deaths per 
17031 person years 
2.8% 
34 deaths per 1208 
person years 
Unadj : 1.72  
(1.19 – 2.47) 
Adj: 1.28  
(0.88-1.85) 
Standard 1.0% a year 
180 deaths per 17 
516 person years 
4.9% a year 
17 deaths per 345 
person years 
 
Unadj: 3.88  
(2.35 to 6.40) 
Adj: 2.87 
(1.73 to 4.76) 
Adjusted hazard ratios are adjusted for age, gender, smoking status, history of cardiovascular 
disease, history of heart failure, peripheral neuropathy, albumin to creatinine ratio, heart rate, QT 
score, visual acuity score, statin use, sulphonuria use, glycaemia intervention, enrolled in lipid v 
blood pressure trial, intensive blood pressure control group, and fibrate group. 
 
Table 3 Mortality rates within treatment groups by occurrence of episodes of SH requiring medical 
intervention in the ACCORD Study (Adapted from (Bonds et al., 2010). 
Tattersall and Gill (Tattersall and Gill, 1991) described sudden and unexpected 
deaths in patients with T1DM and hypothesised that hypoglycaemia was the 
underlying cause.  The majority of patients studied had a previous history of 
nocturnal hypoglycaemia and there was some circumstantial evidence indicating 
hypoglycaemia as a cause of death.  However, nocturnal hypoglycaemia in T1DM 
is common (Amin et al., 2003) and death from this is relatively rare (Klatt et al., 
1988) suggesting a possible predisposing condition that puts a small proportion of 
T1DM patients at risk for sudden death.  One possible predisposing condition is 
DAN. 
 
DAN is also associated with an increased risk of death.  O’Brien et al (O'Brien et 
al., 1991) studied 506 participants with insulin dependent diabetes mellitus 
(IDDM) randomly selected from clinic.  DAN was diagnosed in 84 (16.6%) of 
patients and these patients were matched with a case control group to control for 
sex and duration of diabetes (Table 4).  Five year survival in patients with DAN 
(72.6%) was lower than in those patients in the case control group (91.7%).  
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 Subjects with diabetes 
and DAN (84) 
Case control group (84) 
Sex 36M,48 F 38M.46F 
Age (years) 46±15 46±16 
Duration of diabetes 
(years) 
20 + 9 19±9 
Insulin (u/day) 50 ±22 46±I6 
BMI 24±3 24±3 
Vascular disease 11% 2% 
Retinopathy 75% 30% 
Proteinuria 25% 4% 
Sensory neuropathy 57% 24% 
Table 4 Clinical characteristics of patients (Adapted from (O'Brien et al., 1991)). 
 Subjects with diabetes 
and DAN 
Subjects with diabetes  
without DAN 
Vascular disease 8 7 
Infection 2 3 
Renal failure 10 1 
Malignant disease 2 3 
Trauma/suicide 0 2 
Other 1 1 
Unknown 0 4 
Table 5 Causes of death (Adapted from (O'Brien et al., 1991)). 
 
It is difficult to establish the cause of the increase in mortality and a proportion of 
patients with DAN have reportedly died suddenly and unexpectedly with no cause 
of death found on post-mortem (O'Brien et al., 1991) (Ewing et al., 1980).  The 
relationship is complicated by the tendency of diabetic complications (table 4) to 
occur together and the increased of risk of death caused by renal failure (table 5) 
confirmed by other studies (Ewing et al., 1980).  Ewing studied a group of 73 
patients including 40 patients with proven DAN.  Over a five year follow up 
period 21 subjects with DAN died (53%) compared to 5 (15%) in the control 
group.  Of those that died, 5 died suddenly and unexpectedly with no cause of 
death found at post mortem (Ewing et al., 1980). 
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1.4.3 Hypoglycaemia and Autonomic Nervous System Function  
Hypoglycaemia stimulates a specific response by the autonomic nervous system 
which is well established, but less is known about the wider effects of this 
response, particularly on cardiac autonomic function.  It is plausible that either 
clinical or subclinical DAN could predispose patients to life threatening 
arrhythmias that occur during hypoglycaemia causing sudden death in patients.  
This has started to be considered and recently heart rate variability (HRV) and 
baroreceptor sensitivity (BRS) have been measured during experimental 
hypoglycaemia.   These measurements have sought to establish the effect of 
hypoglycaemia on cardiac autonomic function but the results have been 
conflicting (Laitinen et al., 2003, Schachinger et al., 2004, Koivikko et al., 2005) 
 
Power spectral analysis was introduced by Akselrod et al as a way to understand 
how the different aspects of the nervous system affect HRV (Electrophysiology, 
1996).  HRV in the frequency domain is now commonly used to investigate 
cardiac autonomic function (Gustavo A. Reyes Del Paso et al., 2013).  HRV 
describes the variation in the RR interval, or time between consecutive heart 
beats, on the ECG.  This oscillates continuously around the mean.   
Two oscillatory components are typically defined: the high frequency band (0.04 
to 0.15Hz) which reflects the effect of respiration on the heart rate and the low 
frequency band (0.1Hz) related to blood pressure and vasomotor control (Gustavo 
A. Reyes Del Paso et al., 2013). These components have then been used to 
demonstrate the balance between the two different aspects of the autonomic 
nervous system; the parasympathetic and sympathetic branches (Malliani et al., 
1991).  The sympathetic influence on the RR interval is mediated by adrenaline 
and noradrenaline release and parasympathetic influence is maintained by 
acetylcholine release and the vagus nerve (Electrophysiology, 1996).   
It is accepted that the high frequency band represents parasympathetic or vagal 
activity (Malliani et al., 1994).  The low frequency band is often assumed to 
represent sympathetic activity and then the HF/LF ratio is used to represent the 
balance between the parasympathetic and sympathetic input.  This relies upon the 
belief that the autonomic nervous system is thought to be antagonistic therefore 
with increased activity in the sympathetic system there is reduced activity in the 
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parasympathetic system (Malliani et al., 1994).  More recently the assumption that 
the HF/LF ratio represents the sympatho-vagal balance has been challenged 
(Billman, 2013).  The LF peak is now thought to have a combined vagal and 
sympathetic input and there are certain circumstances when a change in one 
component of the autonomic nervous system does not cause a reciprocal change in 
the other (Billman, 2013).   
BRS measures changes to the RR interval or heart rate in response to changes in 
systolic blood pressure (Bernardi et al., 2011).  In a healthy individual increases in 
systolic blood pressure reduces sympathetic nervous system activity and increases 
parasympathetic, vagal activity causing an immediate reduction in heart rate and 
consequently blood pressure.  Impaired BRS causes a reduction of 
parasympathetic activity and a reciprocal increase in sympathetic activity.   
The clinical use and implications of BRS in diabetes is still unclear.  In cardiology 
abnormal BRS in cardiovascular disease has been shown to be a predictor for 
death and an important prognostic marker (Rovere et al., 2012).  Abnormal BRS 
in patients with diabetes is common in patients with and without autonomic 
neuropathy (Bernardi, 2000).  Some studies have suggested that their data shows 
that BRS can detect DAN at an earlier stage before the classical tests become 
abnormal (Frattola et al., 1997) but to date there hasn’t been the completion of a 
prospective study to provide the evidence for this assumption.  Some studies have 
also suggested that BRS has a functional component by showing normalisation 
with deep breathing (Rosengard-Barlund et al., 2011).  The review undertaken by 
Tesfaye et al (Tesfaye et al., 2010) in 2010 recommended the use of BRS in 
research studies but not for diagnostic purposes in routine clinical practice.         
1.4.4 The Effect of Experimental Hypoglycaemia on Cardiac Autonomic 
Function 
Laitinen and colleagues (Laitinen et al., 2003) hypothesised that the increased 
sympathetic activity during an episode of hypoglycaemia would result in reduced 
cardiac parasympathetic activation based on the concept of the antagonistic 
autonomic nervous system.  Eighteen healthy volunteers were recruited and 
participated in a hyperinsulinaemic euglycaemic clamp (glucose 5.0 mmol/l) 
followed by a hyperinsulinaemic hypoglycaemic clamp (glucose 3.0 mmol/l).  
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Five minute ECG and continuous blood pressure recordings were made at 
baseline, during euglycaemia and hypoglycaemia.   
 
During hyperinsulinaemic hypoglycaemia there was sympathetic activation with 
secretion of adrenaline and noradrenaline but no evidence of parasympathetic 
response with no significant changes in HRV or BRS.  The authors concluded that 
this challenges the antagonistic nature of the autonomic nervous system but 
agreed that although there was pronounced adrenaline secretion they did not 
demonstrate muscle sympathetic nerve activity or sympathetic stimulation to the 
heart.  The other concern is that whether the level of hypoglycaemia (3.0mmol/l) 
is significant enough to provoke a response. 
     
These results were contradicted in a similar study by Schachiger and colleagues 
(Schachinger et al., 2004).  Fifteen healthy adults underwent normoglycaemic 
(4.7mmol/l) and hypoglycaemic (2.7mmol/l) clamps that were carried out four 
weeks apart in a single blinded cross over study.  As in the study by Laitinen et al 
(Laitinen et al., 2003) adrenaline and noradrenaline levels increased during 
hypoglycaemia without an increase in heart rate.  However, there was an increase 
in HF HRV indicating an increase in parasympathetic activity.  They concluded 
that the lack of increase in heart rate during hypoglycaemia was due to the 
increased parasympathetic activity.   
 
The differences may be due to the different clamp protocols.  Laitinen et al 
(Laitinen et al., 2003) carried out both clamps on the same day, used paced 
breathing during the measurement of heart rate variability, and used a higher level 
of hypoglycaemia.  Schachiger et al (Schachinger et al., 2004) separated their 
clamps by four weeks to reduce variation caused by the tests being done at 
different times of day and used a lower level of hypoglycaemia of 2.7 mmol/l.  
They didn’t ask subjects to pace their breathing as they felt this could prove 
difficult to standardise while patients were cognitively impaired during 
hypoglycaemia.  Respiratory rate doesn’t affect the heart rate but has a significant 
effect on HRV.  Slower respiratory rates increase HRV and the increase is seen at 
the frequency band at which the patient was breathing in.  For example LF peak is 
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higher at respiratory rates of 4 and the high frequency HRV is higher at 
respiratory rates of 10, 12 and 14 breaths a minute (Song and Lehrer, 2003).  
 
Koivikko et al (Koivikko et al., 2005) went on to explore the effect of 
hypoglycaemia on cardiac autonomic function in patients with diabetes.  Sixteen 
patients with diabetes with normal baseline cardiac autonomic function tests were 
recruited with eight subjects without diabetes.  HRV was measured during 
euglycaemic (glucose between 4.5 and 5.5 mmol/l) and hypoglycaemic clamp 
studies (glucose 3-3.5 and then 2-2.5 mmol/l) carried out one week apart.  Heart 
rate increased and the HF HRV was reduced indicating reduced parasympathetic 
activity in both the patients with and without diabetes during moderate (glucose 2-
2.5mmol/l) but not during mild hypoglycaemia (glucose 3-3.5mmol/l).   
 
This supports the work by Laitinen et al (Laitinen et al., 2003) in finding no 
changes in heart rate variability in mild hypoglycaemia but contradicts the 
findings by Schachiger et al (Schachinger et al., 2004) that suggested increased 
parasympathetic output during hypoglycaemia.  The differences may be explained 
by the severity and length of time that participants were hypoglycaemic.  
Participants had a more prolonged episode of hypoglycaemia in the Koivikko 
study.   
The studies by Laitinen, Schachiger and Koivikko et al looked at the 
contemporaneous effect of experimental hypoglycaemia on cardiovascular 
autonomic responses.  Adler et al (Adler et al., 2009) explored the downstream 
effect of hypoglycaemia on cardiac AFTs.  Twenty subjects without diabetes were 
recruited for two three-day inpatient visits, separated by a minimum of one month.  
AFTs were carried out on days one and three and a hyperinsulinaemic 
hypoglycaemic or euglycaemic clamp was carried out on day 2 (Figure 5).     
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Figure 5 Two protocols were undertaken by each subject separated in time by at least one month.  
Autonomic function tests were completed on days one and three and a euglycaemic or hypoglycaemic 
clamp study was undertaken on day two (Adapted from Adler et al (Adler et al., 2009)).  
Cardiac vagal BRS was significantly reduced following the hypoglycaemic 
clamps in comparison to the euglycaemic clamps.  There was also a reduction in 
HF HRV following hypoglycaemia.  The authors expressed concern about this 
reduction in parasympathetic activity due to the association of a reduced BRS 
with increased mortality in myocardial infarction patients (Bigger et al., 1993).  
This response may be more severely impaired in patients with diabetes with 
clinical and subclinical autonomic neuropathy but these patients were not included 
in this study. 
 
Summary 
An increased risk of death has been seen in patients suffering repeated episodes of 
SH and those with DAN.  It is plausible that clinical or subclinical DAN could 
predispose patients to life threatening arrhythmias during hypoglycaemia causing 
sudden death.  Experimental work has been done to assess the effect of 
hypoglycaemia on cardiac autonomic function but results have been inconsistent 
and have to date only included patients without classical autonomic neuropathy.  
The inconsistencies seen are most likely due to the different experimental 
protocols undertaken and characteristics of the study participants.   
 
 
July 2018 Page 38 
 
1.5 Aims of the Thesis 
IAH and DAN are important clinical entities in diabetes.  They cause an increase 
in episodes of SH and death respectively.  Classically DAN has been described as 
the underlying mechanism causing IAH but this has been challenged in the 
literature.  To date studies have been unable to clarify the relationship 
successfully due to the complicating and confounding factors of age and duration 
of diabetes. 
It is important to understand the relationship between IAH and DAN.  IAH can be 
at least partially reversed by completely avoiding hypoglycaemia for a period of 
time.  Treatment is often difficult. It requires intensive input from specially 
trained staff and is expensive.   
Patients do not always respond to treatment of IAH.  Two clinical scenarios are 
generally seen: patients with a shorter duration of disease and tight glycaemic 
control and those with a long duration of disease.  It is those patients with a longer 
duration of disease that do not always respond to treatment but it is difficult to 
predict those that will reverse and those who will not improve.   
Ideally a safe and inexpensive test would be available to identify responders and 
non-responders to treatment.  If clinical or subclinical DAN is a factor 
contributing to the potential to reverse IAH then AFTs could be used as a 
predictor to responsiveness to treatment as the tests are simple and non –invasive.   
The increased risk of death seen in patients suffering multiple episodes of SH is a 
current concern.  Potential mechanisms include cardiovascular disease, 
vulnerability because of co morbidities and DAN.  The potential link between 
these entities needs clarification as the currently the literature is inconsistent.   
It is plausible that DAN could be a predisposing condition that would increase the 
risk of death in patients experiencing episodes of SH.  The effect of experimental 
hypoglycaemia on cardiac autonomic function has started to be investigated.  
Differing patient populations and clinical protocols in studies have given 
inconsistent results and the effect of hypoglycaemia on parasympathetic output 
remains undefined. 
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The aim of this research is to investigate the relationship and potential association 
between IAH and DAN.  I have proposed three hypotheses, which have been 
tested in this work and are listed below: 
1) DAN is more prevalent in people with T1DM and IAH compared to 
people with T1DM and normal awareness of hypoglycaemia. 
 
2) The presence of clinical or subclinical DAN impedes the ability to reverse 
IAH in people with T1DM. 
 
3) Experimental hypoglycaemia provokes different cardiac autonomic 
responses in people with T1DM and IAH in comparison to individuals 
with T1DM and normal awareness of hypoglycaemia. 
 
The structure of this thesis reflects the three hypotheses to be investigated.  
Chapter 2 gives a detailed description of the methods used.  The three results 
chapters concentrate on the individual hypotheses with an appropriate 
introduction, method and discussion.  Chapter 6 completes the thesis with a 
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Chapter 2: Methodology 
 
The purpose of this chapter is to describe the methods I used to investigate the 
relationship between impaired awareness of hypoglycaemia (IAH) and diabetic 
autonomic neuropathy (DAN).  The main hypoCOMPaSS (Comparison of 
Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia) 
trial and subsequent autonomic neuropathy sub-study will be described in detail 
including participant inclusion and exclusion criteria.  The hyperinsulinaemic 
hypoglycaemic clamp study protocols including the use of cardiovascular and 
biochemical markers will also be presented.    
2.1 Overview 
The hypoCOMPaSS Trial (Little et al., 2012) was a UK-based, multicentred, 
prospective randomised controlled trial (RCT).  It aimed to optimise diabetes 
treatment in patients with IAH to prevent biochemical hypoglycaemia (BH) and 
restore symptomatic awareness.  The five UK sites involved in the study were 
tertiary referral and academic hypoglycaemia/continuous subcutaneous insulin 
infusion (CSII) centres, and included, Royal Bournemouth Hospital, 
Bournemouth; Addenbrooke’s Hospital, Cambridge; Newcastle Diabetes Centre, 
Newcastle Upon Tyne; Derriford Hospital, Plymouth and Sheffield Teaching 
Hospitals, Sheffield.  The protocol has been published (Little et al., 2012) in full 
but the key features have been described in this chapter.    
 
Detailed cardiac autonomic function testing was carried out during the ‘wash-in 
period’ of the HypoCOMPaSS trial prior to randomisation and intervention.  
Participants were randomised to one of four treatment arms; multiple daily 
injections (MDI) with self monitoring of blood glucose (SMBG), MDI with 
SMBG and real time continuous glucose monitoring (RT-CGM), CSII with 
SMBG and CSII with SMBG and RT-CGM and underwent a six month treatment 
period.  The aim of treatment was to completely avoid BH (glucose less than 
4mmol/l) with an aim of restoring awareness.  Participants had at least weekly 
contact with a member of the hypoCOMPaSS team and were seen face to face 
every 4 weeks to offer support and maximise treatment.  At the end of the 
treatment period cardiac autonomic function testing was repeated (figure 6). 
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Figure 6 Overview of studies. 
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Eligible participants were invited to undergo an optional stepped 
hyperinsulinaemic hypoglycaemic clamp study at the start and end of the 
hypoCOMPaSS trial.  A five minute ECG recording with continuous blood 
pressure readings were made during each glucose step of the clamp.  The 
recordings were analysed to measure heart rate variability (HRV) and baroreflex 
sensitivity (BRS) to investigate cardiovascular and autonomic responses to 
hypoglycaemia.   
 
Following completion of the main hypoCOMPaSS trial I designed a sub-study 
(figure 6) to investigate the relationship between IAH and DAN.  The sub-study 
recruited participants with T1DM and normal awareness of hypoglycaemia to 
match and compare to the hypoCOMPaSS population.  To ascertain if there was 
an association between IAH and DAN, the sub-study participants underwent 
cardiac autonomic function testing, and were invited to undergo a hypoglycaemic 
clamp study if eligible.  I also recruited ten participants without diabetes as a 
control group.  The data from the main hypoCOMPaSS trial and sub-study have 
been used to investigate the three hypotheses listed below. 
 
Hypothesis one: DAN is more prevalent in people with T1DM and IAH compared 
to people with T1DM and normal awareness of hypoglycaemia.  The 
hypoCOMPaSS participants, and participants in the sub-study, underwent detailed 
cardiac autonomic function tests to ascertain the presence or absence of DAN.  
The prevalence of DAN in the two study populations were compared to ascertain 
if there was a difference and an association between IAH and DAN. 
Hypothesis two: The presence of clinical or subclinical DAN impedes the ability 
to reverse IAH in people with T1DM.  Following the six month treatment period 
of the hypoCOMPaSS trial participants were labelled as responders to treatment 
of IAH or non-responders.  The prevalence of DAN in the responder group was 
compared to the prevalence of DAN in the non-responder group. 
Hypothesis three: Experimental hypoglycaemia provokes different cardiac 
autonomic responses in people with T1DM and IAH in comparison to individuals 
with T1DM and normal awareness of hypoglycaemia.  The effect of 
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hypoglycaemia on heart rate variability (HRV) and baroreflex sensitivity (BRS) 
during the clamp studies was compared between the two participant groups. 
2.2 The HypoCOMPaSS Trial 
The aim of the HypoCOMPaSS study was to optimise diabetes treatment in 
patients with IAH to prevent BH and restore awareness.  Patients were 
randomised to either optimised MDI or CSII with or without RT-CGM in a 2x2 
factorial design (figure 7).  The study design complied with the CONSORT 
statement. 
 
Patients recruited and consented 
 
 






                 MDI                                                           CSII    
          MDI          MDI                                          CSII          CSII 
                        & RT-CGM                                                & RT-CGM 
Figure 7 HypoCOMPaSS RCT, a 2x2 factorial design (Adapted from (Little et al., 2012)). 
 
Participants underwent detailed cardiac autonomic function testing during the 4 
week wash-in period of the study, and after the six month treatment period.    All 
eligible participants were also invited to undergo an optional hyperinsulinaemic, 
hypoglycaemic clamp study before, and after the trial, with an aim to objectively 
demonstrate reversal of IAH (Leelarathna et al., 2013).  Cardiac autonomic 
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function was measured during the different glucose steps of the clamp studies in 
centres with suitable recording equipment. 
 
Research Governance 
Ethical approval for this study was sought and gained from Sunderland Research 
Ethics Committee.  Clinical Trial Authorisation was given by the Medicines and 
Healthcare products Regulatory Agency (17136/0246/001-0001).  Site Specific 
Approval was granted by all participating Acute Hospital Trust Research and 
Development Departments (Little et al., 2012). 
 
Study Participants 
Participants were recruited from five UK tertiary referral and academic 
hypoglycaemia/CSII centres: Royal Bournemouth Hospital, Bournemouth; 
Addenbrooke’s Hospital, Cambridge; Newcastle Diabetes Centre, Newcastle upon 
Tyne; Derriford Hospital, Plymouth; Sheffield Teaching Hospitals, Sheffield.  
Individuals with T1DM and IAH were referred by members of the participant’s 
usual clinical team and then assessed to ascertain eligibility for the study.  Those 
that were considered eligible were approached and provided with written 
information about the trial before written consent was obtained. 
 
Inclusion criteria for hypoCOMPaSS trial 
 Male or female aged 18-74 years inclusive at the start of the trial. 
 Diagnosis of diabetes mellitus according to American Diabetes 
Association (ADA) and World Health Organisation (WHO) criteria 
(Appendix 1) and consistent with a clinical diagnosis of T1DM. 
 Serum C-peptide below the quality assured limit of detection for the assay 
with simultaneous exclusion of biochemical hypoglycaemia (glucose <4.0 
mmol/L) by laboratory glucose level analysis on a sample taken at the 
same time point. 
 History of severe hypoglycaemia in the preceding one year (as defined by 
the ADA (Workgroup, 2005) and / or impaired awareness of 
hypoglycaemia as confirmed by a score of ≥ 4 in the Gold score 
(Appendix 2)  
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Exclusion criteria for hypoCOMPaSS trial 
 Any condition that in the investigator’s judgement is likely to cause the 
subject to be unable to understand the information in the Informed 
Consent Document or provide informed consent. 
 A level of English below that to enable the participant to understand both 
verbal and written information required by the study.  
 Unwilling to undertake intensive insulin therapy including the use of CSII, 
optimised MDI regimen and use of RT-CGM. 
 Unwilling to undertake glucose profiles using continuous glucose 
monitoring (CGM). 
 Unwilling to monitor home blood glucose levels at least 4 times daily. 
 Unwilling to monitor and record signs and symptoms of hypoglycaemia. 
 A history of intolerance to insulin Glargine. 
 
Baseline visits and 4 week ‘wash in period’ 
Visit one; screening and consent 
Informed consent was taken before participants entered a four week wash in 
period (Table 6) prior to the 24 week RCT.  Participants were provided with a 
handheld glucometer and were asked to measure a 4 point daily glucose profile 
and a weekly 8 point profile.  Participants were also asked to record all glucose 
levels less than 4mmol/l.  Blood was taken for HbA1c with a paired C-peptide and 
glucose to confirm eligibility.   
 
Visit two; blinded CGM 
All participants attended for the placement of a blinded CGM sensor (Medtronic 
iPro) which was worn for 7 days.  Retinal photography was carried out if not 
completed within the last six months and a urine sample for albumin creatinine 
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 Table 6 HypoCOMPaSS trial visit schedule (Adapted from (Little et al., 2012)). 
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Visit three; baseline assessment and hypoglycaemic clamp study 
A full clinical history and examination was undertaken and blood was taken for 
HbA1c, urea and electrolytes, liver function tests and a lipid profile.  
Hypoglycaemia unawareness was reassessed by the completion of the Gold score 
(Appendix 1).  If the participant was willing to proceed with, and eligible for, the 
hyperinsulinaemic hypoglycaemia clamp study separate consent was obtained.       
 
Hyperinsulinaemic hypoglycaemic clamp studies 
Hyperinsulinaemic hypoglycaemic clamp studies were carried out before and after 
the 24 week intervention period (Table 6) in eligible participants willing to 
undergo the procedure.  Separate written consent was obtained for each study.  
Additional exclusion criteria were applied to ensure patient safety. 
 Age > 60 years 
 History of epilepsy 
 History of ischaemic heart disease 
 Other significant disease which in the judgement of the investigator 
precludes participation.  This included cardiac arrhythmia and heart 
failure, peripheral vascular disease or stroke and a history of  nephropathy 
as demonstrated by elevated serum creatinine accompanied by proteinuria 
(microalbuminuria alone was not an exclusion criterion).  
 
Prior to the clamp study commencing, the CGM sensor fitted at visit two was 
reviewed with their blood glucose diary, to determine if any antecedent BH had 
occurred over the preceding 24 hour period.  This was undertaken to ensure that 
counter-regulatory responses to hypoglycaemia were not attenuated by antecedent 
hypoglycaemia.  Studies were postponed if any CGM and or self monitored 
capillary glucose below 3.0mmol/l were detected for greater than 20 minutes in 
the 12 hours prior to the study.     
 
Participants were admitted to a dedicated clinical research facility at 8am, within 
the respective hospitals on the study day, after fasting from 10pm the previous 
day.  An intravenous cannula was inserted in the antecubital vein on the non-
dominant arm.  Blood glucose levels were stabilised using a sliding scale Actrapid 
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(Novo Nordisk, Baegsvard, Denmark) insulin infusion aiming initially for a blood 
glucose reading of between 6.0 to 7.0 mmol/l reducing to between 5.0 and 6.0 
mmol/l between 10:30am and 11am for the start of the clamp. 
 
A retrograde cannula was inserted in a vein on the dorsum of the hand of the non-
dominant arm using local anaesthetic.  The hand was heated to 50-60 degrees 
using a hotbox, starting at least 30 minutes prior to the start of the clamp, to 
arterialise the blood.  The retrograde cannula was used for sampling and a slow 
intravenous infusion of saline was used to keep the line patent.     
 
At 11am, a primed infusion of 60mU/m2/min soluble human Actrapid insulin in a 
4% solution of autologous blood in 0.9% saline was started via the non-dominant 
antecubital vein catheter.  A simultaneous infusion of 20% dextrose, via the same 
antecubital catheter, was adjusted as required, aiming to stabilise the blood 
glucose at 5.0mmol/l at 40 minutes.  Blood glucose was then lowered in a step 
wise manner to 3.8mmol/l, 3.4mmol/l, 2.8mmol/l and 2.4mmol/l.  Plasma glucose 
was sampled from the retrograde cannula every 5 minutes, spun rapidly and 
assayed using Yellow Springs glucose analyser (YSI STAT Plus, Farnborough, 
U.K.).  Each step consisted of 40 minutes, allowing 20 minutes to fall to target 
and 20 minutes for stabilisation.  Participants were blinded to glucose levels 
throughout the study. 
 
In addition to samples for plasma glucose, additional arterialised, venous blood 
samples for insulin, metanephrines, cortisol, growth hormone and electrolytes 
were drawn at the start of the clamp and at least every 40 minutes thereafter.  
Heart rate and blood pressure measures were taken with a 2 minute ECG 
recording every twenty minutes.  At the end of each clamp stage participants 
completed the Edinburgh Hypoglycaemia Score (Appendix 3 (Deary et al., 
1993)). 
 
At each glucose step a five minute ECG recording with continuous blood pressure 
monitoring was completed to assess HRV and BRS.  This allowed a non-invasive 
assessment of cardiac autonomic responses during euglycaemia and 
hypoglycaemia.  The methodology of recording and interpreting HRV and BRS 
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are discussed in detail below.  During the clamp studies recordings were 
undertaken with the participants at rest with spontaneous breathing.  Current 
recommendations state that HRV should be assessed while the patient’s breathing 
is paced (Tesfaye et al., 2010) or measured to ensure accurate interpretation of 
HRV.  During the hypoglycaemic clamp the respiratory rate was measured rather 
than attempting to pace breathing due to concerns about consistency because of 
potential cognitive impairment during hypoglycaemia.  Recordings of the 
respiratory rate ensured that the rate was between 10 and 15 breaths per minute in 
all participants during each recording (Guzik et al., 2007).    
 
At the end of the clamp study the dextrose infusion was increased to raise blood 
sugar to euglycaemia and then tapered off gradually during a carbohydrate rich 
meal.  The insulin infusion was reduced to basal requirements.   Frequent blood 
glucose measurements were made until glucose levels were stable.  Participants 
were discharged with advice about their subsequent insulin doses. 
 
HRV 
Heart rate is constantly changing under the influence of parasympathetic and 
sympathetic input (Vander et al., 1998) and HRV describes this variation in the 
RR interval, or time between consecutive heart beats, on the ECG.  Stimulation of 
the vagus nerve will reduce heart rate which has been shown in animal studies in 
healthy anaesthetised dogs (Hamlin and Smith, 1968).  Human studies have 
confirmed this with stimulation of the vagal nerve during radical neck dissection 
(Carlsten et al., 1957). 
HRV oscillates continuously around the mean.  Time domain measurements of the 
RR interval explore parasympathetic activity (Bernardi et al., 2011).  These 
include the difference between the longest and shortest RR intervals, the standard 
deviation of the average RR intervals in a five minute recording (SDRR) and the 
root mean square of the difference of successive RR intervals (RMSSD)   
Further information about heart rate variability can be gained by measuring the 
fluctuation in the frequency domain (Bilchick and Berger, 2006).  The RR 
intervals are converted to a power spectral density function by a computational 
algorithm called the fast Fourier transform.  The power spectral analysis is usually 
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integrated into specific frequency bands as fluctuations in each band are mediated 
by specific physiological mechanisms (Bilchick and Berger, 2006). 
Two frequency bands are commonly defined; the high frequency (HF) band (0.15-
0.40Hz) which reflects the effect of respiration on heart rate and the low 
frequency band (LF) (0.04-0.15Hz) reflecting variation related to blood pressure 
and vasomotor tone (Paso et al., 2013).  It is widely accepted that the HF 
component of the spectrum represents vagal or parasympathetic activity (Bernardi 
et al., 2011, Berntson et al., 1997).  The evidence for this was first shown in dogs 
in 1981 (Akselrod et al., 1981) and confirmed in human studies in 1985 
(Pomeranz et al., 1985).  The Toronto Diabetic Neuropathy Group recommended 
that heart rate spectral power in the high frequency region can be used as a 
measure of parasympathetic modulation in their most recent consensus statement 
(Tesfaye et al., 2010).  The effect of respiration must be considered either by 
adjusting for the respiratory rate or by controlling respiratory rate when 
interpreting HF heart rate variability (Berntson et al., 1997). 
The interpretation of the LF band is more controversial (Gustavo A. Reyes Del 
Paso et al., 2013).  The initial evidence for the LF band being linked to 
sympathetic activity came from studies examining the effect of passive orthostatic 
tilt on HRV (Montano et al., 1994) when passive tilt was shown to increase LF 
and decrease HF.  This work has been challenged (Berntson et al., 1997, 
Electrophysiology, 1996) and it has been suggested that LF represents both 
sympathetic and parasympathetic input.  As a result the LF/HF ratio is used by 
some groups to illustrate sympathovagal balance (Electrophysiology, 1996).  
HRV measures indicate fluctuations in autonomic inputs and therefore 
parasympathetic withdrawal and sympathetic increases can lead to reduced HRV.   
Normalised LF (LF norm) was suggested as an alternative marker of sympathetic 
activation and units are obtained by dividing LF by the total power (Gustavo A. 
Reyes Del Paso et al., 2013).  This has been accepted as a marker of sympathetic 
activity by the Toronto Diabetic Neuropathy Expert Group (Tesfaye et al., 2010).  
It however should be interpreted with care and some groups still recommend 
Baroreflex control of heart rate as a more accurate measure of sympathetic 
activity (Paso et al., 2013). 
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The most recent recommendations from the Toronto Diabetic Expert Group 
(Tesfaye et al., 2010) state that  both time domain and frequency domain 
measures of HRV can be used in clinical trials and research.  Recordings should 
be 5-7 minutes in length.  HF power can be used as a measure of parasympathetic 
activity and LF power can be used as a measure of both parasympathetic and 
sympathetic input.  Respiratory rate should be measured or controlled to ensure 
accurate interpretation of power spectral analysis measures. 
HRV Analysis 
In these studies HRV analysis was carried out in accordance with the 
recommendations by the Toronto Diabetic Neuropathy Expert Group in the ADA 
update statement published in 2010 (Tesfaye et al., 2010).  HRV was calculated 
on five minute ECG recordings where the respiratory rate was measured during 
spontaneous breathing with normal tidal volumes.  Time domain measures were 
calculated including SDNN and RMSSD and power spectral analysis was 
performed using the Fast Fourier Transformation.  The HF band was defined as 
0.15 to 0.4 Hz and the LF band between 0.04 to 0.15 and LF norm was defined as 
the ratio between LF and total power.  Ectopic beats were excluded to ensure 
reliability of the measures presented.   
 
BRS  
BRS is a measure of the changes in RR intervals produced by changes in blood 
pressure (Fisher, 2003).  An increase in arterial blood pressure causes stretch in 
the arterial walls stimulating the baroreceptors in the carotid sinus.  Inhibition of 
the sympathetic system and stimulation of parasympathetic system follows, 
causing a reduction in peripheral resistance and lowering of the heart rate, 
resulting in a reduction in blood pressure (Swenne, 2013). 
 
Previously, measurement of BRS was an invasive procedure requiring arterial 
cannulation, but this can now be done by non-invasive measurement of beat to 
beat blood pressures using the Finapres.  The Finapres is based on the Penaz 
technique (Wesseling, 1990) of measuring blood volume in the artery 
photoelectrically and changing the pressure of an inflatable cuff to keep the blood 
volume constant.  With this apparent fixing of the volume in the artery there is an 
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assumption that the extra-arterial pressure is equal to, and can be used as, an 
indirect measure of intra-arterial pressure.   The technique requires application of 
a small finger cuff and the intra-arterial pressure equates to the cuff pressure 
which can be measured with a manometer.    This method has been validated 
against intra-arterial recordings (Omboni et al., 1993). 
 
During these studies BRS was measured non-invasively using the portapres 
device; a portable Finapress (TNO Biomedical Instrumentation Amsterdam, 
Netherlands) with simultaneous ECG monitoring using an Ivy Cardiac Trigger 
Monitor 3000 (Ivy Biomedical Systems Inc, USA).  A finger cuff of the correct 
size was selected and applied to the middle finger of the right hand with the 
frontend unit attached to the wrist.  The Height Correction Unit was nulled and 
then attached to the upper arm at the height of the heart.  Initially on starting the 
device the internal calibration system was switched on until consistent readings 
were obtained and then it was turned off.  Blood pressure data was digitised with a 
sampling frequency of 1000 Hz and synchronised with the ECG data by WR 
TestWorks
TM
 software.  Recordings were made for five minutes with the study 
participant at rest and lying flat.       
 
BRS was calculated and analysed using Nevrokard
TM
 BRS version 5.1.3 
(Intellectual Services Slovenia) using the sequence method (Omboni et al., 1993).  
The sequence method measures BRS as the slope of the relationship between 
changes in systolic blood pressure and subsequent changes in the RR interval 
(Kardos et al., 2001).  An 'UP' sequence was generated with an increase in systolic 
blood pressure of at least 0.5 mmHg associated with an increase in the R-R 
interval of at least 5 ms for three or more consecutive beats. A 'DOWN' sequence 
was identified where there was a reduction in systolic blood pressure of at least 
0.5 mmHg with a corresponding decrease in the R-R interval of at least 5 ms for 
three or more consecutive beats.  The total BRS (ms/mmHg) was calculated using 
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Visit four; cardiac autonomic function testing 
Cardiovascular reflex tests were used to assess cardiac autonomic function.  The 
tests are widely accepted to provide an objective diagnosis of abnormalities in the 
autonomic nervous system (Ewing et al., 1985) (Tesfaye et al., 2010).  The testing 
gives an indication of severity and are safe, non-invasive and can be done at the 
bedside (Neurology, 1996).   
 
Autonomic testing evaluates the physiologic responses to various stimuli 
(Gibbons et al., 2014).  Heart rate response to deep breathing, standing and to the 
valsalva manoeuvre depend upon vagal, parasympathetic innervations (Vinik et 
al., 2003).  Blood pressure response to standing is mediated by sympathetic nerve 
fibres (Vinik et al., 2003).  
 
Tests were carried out as initially described by Ewing in 1982 (Ewing and Clarke, 
1982) with the modifications recommended by O’Brien published in 1986 
(O'Brien et al., 1986).  Results were compared against the O’Brien age adjusted 
normal ranges (O'Brien et al., 1986) with the results below the 95% confidence 
limits regarded as abnormal.  Based on the most recent consensus (Tesfaye et al., 
2010) the presence of one abnormal cardiac reflex tests identifies possible cardiac 
autonomic neuropathy and at least two abnormal heart rate tests are required for a 
definite diagnosis.  Orthostatic hypotension in addition to heart rate reflex test 
abnormalities identifies more severe or advanced disease (Tesfaye et al., 2010).  A 
further five minute ECG recording was made with continuous blood pressure 
monitoring to ascertain HRV and BRS at rest. 
 
To ensure the tests were not influenced by external factors participants were asked 
to refrain from smoking and caffeine on the day of the tests.  If the participant was 
taking a beta blocker this was discontinued 48 hours prior to autonomic function 
testing.  A period of 3 minutes of rest preceded each test and all tests were carried 
out in a darkened room where noise was kept to a minimum. 
 
Cardiac autonomic function testing was completed at each site using local 
equipment.  The raw ECG recordings were exported and analysed at Sheffield 
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Teaching Hospitals, Sheffield, UK.  Custom built semi-automatic software was 
developed to detect QRS complexes from the ECG recordings and the RR 
intervals were used for further analysis. The algorithm automatically detected 
QRS complexes in the ECG recordings based on the threshold method. In the first 
stage, the ECG recordings were smoothed using a low-pass filter with a 40Hz cut-
off frequency. R peaks were then detected as peaks above a predefined threshold 
value which was initially calculated as 3 times the standard deviation above the 
mean of the ECG recording. The detection of R peaks was visually inspected and 
the threshold was adjusted if necessary. All peaks were visually inspected and 
manually corrected to exclude movement artefacts and ectopic beats.  
   
Spectral analysis of HRV was performed based on 5 minute resting ECG 
recordings with the subject supine with spontaneous breathing in accordance with 
recommendations of the Taskforce on Heart Rate Variability (Electrophysiology, 
1996). Normal RR intervals (NN) were extracted as described in the previous 
paragraph for heart rate variability analysis. The time domain measures of HRV 
included standard deviation of NN (SDNN) and root mean square of standard 
deviation (RMSSD). Fast Fourier transform was applied to NN time series for 
spectral analysis and the power was calculated within two frequency bands: low 
frequency (LF: 0.04-0.15 Hz) and high frequency (HF: 0.15-0.4 Hz) 
(Electrophysiology, 1996). The ratio between the LF power and total power (sum 
of low and high frequency power) was also calculated (LFnorm), which has been 
associated with sympathetic modulation in heart rate variability (Bernardi et al., 
2011). 
 
In Sheffield ECG signals were obtained using a three lead ECG monitor (Ivy 
Cardiac Trigger Monitor 3000, Ivy Biomedical Systems Inc., Branford CT, USA), 
which generates a synchronised pulse at the peak of each R wave. This was 
connected to the WR TestWorks™ Analogue Interface (WR Medical Electronics 
Company, Maplewood, USA) and ECG signals were digitised using a sampling 
frequency of 1000 Hz via a data acquisition device (NI-DAQCard-6062E, 
National Instruments™, UK) connected to a laptop computer (Toshiba Satellite 
1800-S274). Data were recorded and analysed using the WR-TestWorks™ 
software (version 2.4.0, WR Medical Electronics Co., Maplewood, USA). This 
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software contained dedicated modules for the heart rate response to deep 
breathing, Valsalva, and standing. A marker was placed on the ECG recording 
denoting the beginning of the manoeuvre and R-R intervals (measured in ms) 
were generated within the programme, with the tests results calculated according 
to definitions below. 
 
Heart Rate Response to Deep Breathing 
Participants were asked to remain supine and breathe deeply at a rate of one 
breath per 10 seconds (six breaths per minute) for one minute while an ECG was 
recorded continuously. A light box was used to indicate when the participant 
should inspire and expire to improve the reproducibility of this test. It was 
expected that the heart rate would increase on inspiration and fall with expiration. 
The Expiration: Inspiration ratio (E:I) was calculated by taking the mean of the 
longest R-R intervals during deep expirations to the mean of the shortest R-R 
intervals during deep inspirations.  
 
Heart Rate Response to the Valsalva Manoeuvre 
The participant was asked to forcibly exhale into a modified sphygmomanometer 
to a pressure of 40mmHg for 15 seconds. Once the valsalva is released subjects 
were asked to lie still without talking and the ECG recording was continued for a 
further 45 seconds.  The expected reflex response to the Valsalva manoeuvre 
includes tachycardia and peripheral vasoconstriction during strain, followed by an 
overshoot in blood pressure and bradycardia after release of strain.  The Valsalva 
R/R ratio was calculated as the highest RR interval after the manoeuvre divided 
by the lowest RR interval during the manoeuvre.  The Valsalva manoeuvre was 
not undertaken by participants with proliferative retinopathy to prevent retinal 
haemorrhages that can be precipitated by sudden increases in intrathoracic 
pressure (Duane, 1972). 
 
Heart Rate Response to Standing 
The participant was connected to the ECG while lying down and then stood to a 
full upright position. In a normal response there is a characteristic and rapid 
increase in heart rate in response to standing that is maximal at approximately the 
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15th beat after standing. This is followed by a relative bradycardia that is maximal 
at approximately the 30th beat after standing.  The 30:15 ratio was calculated as 
the ratio of the longest R-R interval to the shortest R-R interval.  If the maximum 
and minimum R-R intervals did not occur at exactly the 15th or 30th beats after 
standing the 30:15 ratio was redefined as the longest R-R interval during beats 
20–40 divided by the shortest R-R interval during beats 5–25 (Ziegler et al., 
1992). 
 
Systolic Blood Pressure Response to Standing 
Blood pressure was measured using an automatic sphygmomanometer with the 
patient having remained supine for greater than 5 minutes and then repeated one 
minute after standing. A drop of systolic blood pressure >20mmHg is classified as 
abnormal (Witte et al., 2005).  
 
Visit 5; Autoimmune disease screening 
Participants attended for a short synacthen test to exclude adrenocortical 
insufficiency, blood sampling for thyroid stimulating hormone assay to exclude 
thyroid disease and anti-endomysial antibody analysis to exclude coeliac disease.  
Participants with a new diagnosis or uncontrolled concomitant autoimmune 
disease were referred for assessment and treatment before continuing in the study.  
A new diagnosis did not preclude ongoing participation.     
 
Visit 6; Education session 
All participants attended an education session to complete the ‘My Hypo 
COMPaSS tool’, as described in the pilot study and main study protocols  
(Thomas et al., 2007, Little et al., 2012).  The session lasted up to 3 hours and 
participants attended individually or in small groups facilitated by a clinical 
research fellow, diabetes specialist nurse or a specialised dietician.  Discussions 
and exercises explained the importance of completely avoiding hypoglycaemia 
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Randomisation was administered by Newcastle Clinical Trials Unit using a secure 
web based system (Little et al., 2012).  Treatment intervention was stratified by 
centre and baseline HbA1c (cut off  64 mmol/mol or 8%).  Participants were 
allocated to one of four interventions by a third party: 
 MDI with SMBG 
 MDI with SMBG and RT-CGM 
 CSII with SMBG 
 CSII with SMBG and RT-CGM 
 
Following randomisation all participants attended an educational session (Little et 
al., 2012) regarding the technical aspects of their treatment arm.  All participants 
were provided with a Medtronic Veo insulin pump and instructed how to use the 
bolus calculator whether or not insulin was being delivered by CSII.  All 
participants were provided with a Contour link SMBG meter with direct 
transmission of blood glucose values to the insulin pump bolus calculator.   
 
The common goal of each intervention was to completely avoid blood glucose 
levels of less than 4mmol/l determined by SMBG and RT-CGM.  Participants 
were instructed to treat all blood glucose levels of less than 4 mmol/l with 15g of 
carbohydrate with repeat testing 15 minutes after treatment and repeated treatment 
if required.  Following treatment insulin dose reduction was then to be considered. 
 
a) MDI 
Participants randomised to MDI were provided with insulin aspart, 3ml 
cartridge with 100 Units/mL, in a disposable pen (Flexpen) and insulin 
glargine, 3ml cartridge with 100 Units/mL, in a disposable pen (SoloStar).  
Insulin lispo, 3ml cartridge with 100 Units/mL in a disposable pen (Kwikpen), 
was offered if participants had a previous negative experience or adverse 
reaction to insulin aspart. Participants were taught how to use the pens and 
received information about injection site care.  Participants were also provided 
with a Medtronic Veo insulin pump and were taught how to use the bolus 
calculator. 
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Insulin glargine was advised to be taken within 30 minutes of retiring to bed.  
Participants were told to aim for a stable blood glucose overnight.  Doses were 
advised to be reduced in the event of any nocturnal hypoglycaemia or if blood 
glucose levels were less than 5.0mmol/l between 4am and breakfast.  Doses 
were advised to be adjusted by 1-2 units if the fasting target was not achieved 
but not at the expense of hypoglycaemia. 
 
If blood glucose levels were greater than 7.0mmol/l pre-evening meal or very 
variable before breakfast and evening meal then a second dose of glargine was 
introduced at 4 units.  The evening dose was reduced by 2-4 units if there was 
evidence of a reducing blood glucose overnight preceding the introduction of 
the second dose.  Participants taking glargine twice a day on entering the trial 
were advised to continue if randomised to MDI. 
 
The second dose of glargine was advised to be taken within 30 minute of 
rising.  Stable blood glucose levels were aimed for during the afternoon.  
Doses were reduced if any hypoglycaemia occurred during the period of time 
between 2 hours post lunch and the evening meal.  Doses were advised to be 
adjusted by 1-2 units if the pre-evening meal target was not achieved but not 
at the expense of hypoglycaemia.  
 
b) CSII 
All participants randomised to CSII were provided with insulin aspart in 10ml 
vials with 100 Units/mL.  Insulin lispo was offered to participants with a 
previous negative experience or adverse reaction to insulin aspart.  
Participants received information about the technical aspects of the pump 
including the changing of infusion sets during the education session.      
 
The basal rates were titrated according to fasting, pre-meal, pre-bed and 4am 
targets.  If within targets no changes were made.  If above target the basal 
insulin was increased by 0.1units/hour from the previous checkpoint.  If below 
target the basal insulin was reduced by 0.1units/hour.   
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c) SMBG 
All participants received information about the technical aspects of using the 
Contour link meter which was able to transmit data automatically to the bolus 
calculator on the pump.  All participants were asked to check blood glucose 
levels four times a day and then undertake a weekly 8 point profile including 
those using RT-CGM.   
 
d) RT-CGM   
Participants randomised to RT-CGM were provided with a MiniLink Real-
Time Transmitter which was connected to the participant’s insulin pump to 
allow the display of CGM data.  Participants were informed about how to use 
the hypoglycaemic and hyperglycaemic alarms and trend analysis.  
Participants were shown how to use the data to alter their insulin doses during 
real time and retrospectively.   
 
Meal time insulin (CSII and MDI) 
Insulin aspart or lispro were given either by subcutaneous injection or as a pump 
bolus before meals or snacks with a carbohydrate content of greater than 10g.  
Carbohydrate counting skills were evaluated in each individual during the 
education sessions.  Individualised insulin carbohydrate ratios and insulin 
sensitivity factors were calculated.  Insulin: carbohydrate ratios were calculated 
using the ‘500 rule’: 500 divided by the total daily dose of insulin (pre-
randomisation) equals the grams of carbohydrate covered by one unit of aspart or 
lispro insulin. 
   
Corrective doses were recommended to be given with the meal time bolus if pre-
prandial blood glucose levels were above target.  This was calculated by the ‘100 
rule’: 100 divided by the total daily dose of insulin equals the glucose reduction in 
mmol/l per 1 unit of insulin aspart or lispro.  The insulin: carbohydrate ratio and 
insulin sensitivity factor would be adjusted if an unexplained episode of 
hypoglycaemia occurs within 2 hours of a meal or if glucose levels are 
consistently above or below blood glucose target 2 hours after a meal.   
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Blood Glucose Targets 
 Fasting blood glucose: 5.0 to 7.0mmol/l 
 Pre-prandial blood glucose: 4.5-7mmol/l 
 Post-prandial (2 hours) blood glucose 6.0-8.0mmol/l 
 Pre-bed blood glucose (within 30minutes of retiring): 6.0-8.0mmol/l 
 4am blood glucose: 5.0-7.0mmol/l 
 
Follow up and support 
Participants were telephoned daily for the first week after commencement of the 
study intervention and at least weekly there after throughout the six month RCT.  
Participants attended for a study visit every 4 weeks for the collection of their 
diaries and for a HbA1c.  A blinded CGM device (Medtronic iPro) (Tan et al., 
2016) was fitted and worn during the week before this visit.  A further 
hypoglycaemic clamp study was carried out during the last visit in willing and 
eligible participants.  Cardiac autonomic function testing was completed at the 
end of the RCT during a separate visit.  Participants were invited to attend three 
follow up visits at 6months, 12 months and 18 months after the RCT was 
completed. 
2.3 The HypoCOMPaSS Sub-study 
 
Following the completion of the HypoCOMPaSS trial I designed a sub-study to 
recruit a control group to compare to the main hypoCOMPaSS population.  
Participants with T1DM and normal awareness of hypoglycaemia were recruited.  
The control population underwent cardiac autonomic function testing to ascertain 
the presence or absence of autonomic neuropathy and were then invited to 
undergo an optional hypoglycaemic clamp study.  Ten participants without 
diabetes were also recruited. 
 
Research Governance 
Ethical approval for this study was sought and gained from Yorkshire and 
Humber Research Ethics Committee (12/YH/0035).  Local approval was sought 
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and granted by Sheffield Teaching Hospitals Foundation Trust 
(STH16283/CSP94410).   
 
Study Participants 
Sub-study participants were recruited from Sheffield Teaching Hospitals, 
Sheffield.  Potential study participants were identified when attending routine 
clinic appointments and were provided with written information.  Permission was 
obtained to allow a member of the research team to contact these potential 
participants at a later date to discuss the study further.  Eligibility and written 
consent were then confirmed and obtained in compliance with good clinical 
practice at visit one.  An optional hyperinsulinaemic hypoglycaemic clamp study 
was discussed at visit one with eligible volunteers.  
 
Inclusion criteria for the hypoCOMPaSS sub-study 
 Male or female aged 18-74 years inclusive at start of the trial. 
 Diagnosis of diabetes mellitus according to ADA and WHO criteria 
(Appendix 1) and consistent with a clinical diagnosis of T1DM. 
 Serum C-peptide below the quality assured limit of detection for the assay 
and laboratory with simultaneous exclusion of biochemical hypoglycaemia 
(glucose <4.0 mmol/L) by laboratory glucose level analysis on a sample 
taken at the same time point.   
 Normal awareness of hypoglycaemia as confirmed by a score of < 4 in the 
Gold score (Appendix 2). 
 
Exclusion criteria for the hypoCOMPaSS sub-study 
 Any condition that in the investigator’s judgement is likely to cause the 
subject to be unable to understand the information in the Informed 
Consent Document or provide informed consent. 
 Patients that are taking beta blocking medication which cannot be 
discontinued safely for 48 hours. 
 
Relatives or spouses of the main hypoCOMPaSS trial study participants and 
members of staff from the diabetes department of Sheffield Teaching Hospitals, 
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Sheffield were invited to take part in the hypoCOMPaSS sub-study as participants 
without diabetes.  All participants underwent a hyperinsulinaemic, hypoglycaemic 
clamp study.  The exclusion criteria for participants without diabetes are more 
extensive than that of the T1DM participants to ensure safety during the clamp 
study. 
 
 Inclusion criteria  
 Male or female aged 18-60 years inclusive at start of the trial. 
Exclusion criteria  
 Any condition that in the investigator’s judgement is likely to cause the 
subject to be unable to understand the information in the Informed 
Consent Document or provide informed consent. 
 Patients that are taking beta blocking medication which cannot be 
discontinued safely for 48 hours. 
 Random glucose > 11.1mmol/l or HbA1c > 48mmol/mol 
 History of epilepsy 
 History of ischaemic heart disease, cardiac arrhythmia or heart failure 
 History of peripheral vascular disease or stroke  
 History of nephropathy as demonstrated by elevated serum creatinine 




After informed consent a full clinical history and physical examination was 
completed and recorded in accordance with the main study.  Blood was taken for 
HbA1c, C-peptide (in participants with T1DM), glucose and urea and electrolytes 
with an ECG.  The hypoglycaemic clamp study was discussed with eligible 
T1DM participants and all participants without diabetes. 
 
Cardiac autonomic function testing 
All participants underwent detailed cardiac autonomic function testing as 
described in the main hypoCOMPaSS study visit 4. 
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Hyperinsulinaemic hypoglycaemic clamp study 
The willing and eligible participants with diabetes and all participants without 
diabetes underwent a hyperinsulinaemic hypoglycaemic clamp study.  The 
procedure was carried out as described in the main hypoCOMPaSS trial.  
Participants with T1DM were fitted with a blinded CGM sensor (Medtronic iPro) 
five to seven days prior to the clamp study.  This was reviewed with their blood 
glucose diary to determine if any antecedent BH had occurred over the preceding 
24 hour time period to ensure that counter-regulatory responses to hypoglycaemia 
were not attenuated by antecedent hypoglycaemia.  Studies were postponed if any 
CGM and or self monitored capillary glucose below 3.0mmol/l were detected for 
greater than 20 minutes in the 12 hours prior to the study.     
 
 2.4 Statistical Analysis 
Power and sample size considerations 
Based upon a previous study with a not dissimilar age and duration of diabetes 
expected in these studies (Hepburn et al., 1990) a reasonable estimate of 
prevalence of autonomic neuropathy in patients with normal awareness of 
hypoglycaemia was 37% and in patients with IAH 63%.  Hepburn and colleagues 
compared the prevalence of DAN depending upon symptomatic awareness of 
hypoglycaemia and duration of disease.  Participants underwent cardiac 
autonomic function testing.  Each test was scored:0 for normal, 1 for borderline 
and 2 for abnormal.  Participants were then given an autonomic score.  A score of 
above 3 were considered to have definite autonomic dysfunction.  They found that 
IAH was associated with a long duration of disease but not invariably associated 
with DAN.   
 
The expected dropout rate of the hypoCOMPaSS studies was expected to be low.  
An allowance was made for a 5% withdrawal rate.  To have 90% power, to detect 
a difference in prevalence of autonomic neuropathy between the groups, based on 
the figures from the Hepburn study, 80 patients with IAH and 80 patients with 
intact awareness would need to be recruited and undergo AFTs.  . 
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Statistical tests 
Data that followed an approximate normal distribution was summarised using 
mean (standard deviation (SD)) unless otherwise stated, whilst skewed data were 
summarized using the median (interquartile range).  Spectral HRV parameters 
were logarithmically transformed to approximate a normal distribution.  Statistical 
analysis was performed with SPSS (version 22.0, IBM, Chicago, Illinois). A p-
value ≤ 0.05 was deemed statistically significant.  
 
Comparison of the prevalence of DAN between the two groups of participants 
defined by awareness of hypoglycaemia was completed with the chi square test 
(for independence).  Potential confounding factors of age, duration of diabetes, 
sex and pre-existing micro- and macrovascular complications were examined 
using an independent t test.  The impact of duration of diabetes was explored 
further using a model of logistic regression; awareness of hypoglycaemia was 
defined as the categorical variable and duration of disease as a predictor variable.  
 
Following the 24 week RCT a comparison of baseline and end HbA1c, insulin 
dose, gold score and number of episodes of SH were compared using a paired t 
test.  Participants were divided by cardiac autonomic status, and change in gold 
score between groups, was compared using chi square test.  Potential confounding 
factors of age, duration of diabetes, sex and pre-existing micro- and 
macrovascular complications were examined using one way analysis of 
covariance (ANOVA).   
 
During the clamp studies changes in metanephrines were analysed using 
ANCOVA.  To compare symptom scores during the clamp, area under the curve 
was calculated for each person, and then ANOVA was used to test for a difference 
in the mean area under the curve.  Differences between mean heart rates of each 
group were calculated using a mixed effects repeated measures model.  Heart rate 
at 60 minutes, 100 minutes, 140 minutes and 180 minutes were defined as 
dependent variables and heart rate at 20 minutes independent with a fixed factor 
for time and for patient group with an interaction term for time and group.  Post 
hoc analysis was completed with the Holm procedure (Aickin and Gensler, 2011).   
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Glucose thresholds for the release of metanephrine were defined as the measured 
glucose at the time of onset of a sustained (≥2 successive time points) increase in 
hormone concentrations ≥ 2SD above the mean baseline measurements.  
Thresholds for the increase in total, autonomic and neuroglycopenic symptoms 
were determined as the measured glucose level at which the symptom score 
increased ≥ 2 over baseline on two consecutive assessments (Choudhary et al., 
2009).  Where no defined change occurred the lowest glucose measurement 
recorded for the participant was used as the threshold for that individual 
(Choudhary et al., 2009) 
 
2.5 Biochemical Analysis 
Blood samples taken during visit one including glucose, c-peptide and HbA1c 
were analysed in local laboratories.  Autoimmune screening and assessment of 
renal function were also analysed in each individual centre.  During the clamp 
studies arterialised plasma glucose was analysed in real time using Yellow 
Springs analyzer (YSI STAT Plus, Farnborough, U.K.) (intraassay coefficient of 
variation (CV) 1.5% and interassay CV 2.8%).  Plasma insulin was measured by 
ELISA (Dako, Glostrup, Denmark) (intra-assay CV 1.8% and interassay CV 
7.8%).  Glucagon was measured by ELISA (Alpco Diagnostics) (intra-assay CV 
1.6% and interassay CV 2.4%).  Cortisol levels were measured using a two-step 
sandwich immunoassay (Roche Modular E-170 platform, Elecsyscortisol 
reagents) (intra-assay CV 1.4% (based on a mean value of 593 nmol/L) and 
interassay CV 4.7% (based on a mean value of 535 nmol/L). Plasma metanephrine 
(separate from normetanephrine) was measured using ELISA (Alpco Diagnostics) 
(intra-assay CV 12% (based on a mean value of 652 pmol/L) and interassay CV 
12.2% (based on a mean value of 350 pmol/L). Growth hormone was measured 
using ELISA (Alpco Diagnostics) (intra-assay CV 1.4% and interassay CV 4.5%).   
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Chapter 3: The Association between Impaired Awareness of 
Hypoglycaemia and Diabetic Autonomic Neuropathy in Type 
One Diabetes Mellitus. 
3.1 Abstract 
Background: Impaired awareness of hypoglycaemia (IAH) affects 20-25% of 
people with type 1 diabetes (T1DM) (Geddes et al., 2008) and increases the risk 
of severe hypoglycaemia (SH) (Gold et al., 1994).  Traditionally, diabetic 
autonomic neuropathy (DAN) has been described as the underlying mechanism 
causing IAH (Vinik et al., 2003) but the literature is conflicting and the 
relationship in confounded by duration of disease (Stephenson et al., 1996, Ryder 
et al., 1990).  This study investigates the relationship between DAN and IAH by 
comparing the prevalence of cardiac autonomic neuropathy in patients with 
T1DM and IAH and a control group of patients with T1DM and intact awareness 
of hypoglycaemia.   
Methods: Participants with impaired awareness of hypoglycaemia (Gold score 
≥4), recruited to the hypoCOMPaSS trial (Little et al., 2012), underwent detailed 
cardiac autonomic function testing prior to study intervention.  Participants with 
normal awareness of hypoglycaemia (Gold score <4), matched for glycaemic 
control and duration of disease underwent the same testing protocol.  The 
prevalence of cardiac autonomic neuropathy in both populations was compared.  
Results: A total of 93 participants with IAH and 51 participants with intact 
awareness of hypoglycaemia underwent detailed cardiac autonomic function 
testing.  Participants with IAH had a higher gold score (IAH gold score 5, intact 
awareness gold score 2, p=<0.005) and an increased incidence of episodes of 
severe hypoglycaemia (IAH median of 4 (7) episodes per year, intact awareness 0 
(0) episodes per year).  Both participant groups had a long duration of disease 
(intact awareness 21 (11) years, IAH 29 (12) years), and despite attempting to 
match the duration of disease the participants with IAH had a significantly longer 
duration of disease (p=0.001).  The overall prevalence of DAN, defined as an 
abnormality in at least two cardiac reflex tests, was low in both participant groups 
(intact awareness 2/51 (4%) and IAH 5/93 (5%)).  There was no statistical 
difference in cardiac autonomic status between the two groups (p=0.37).   
Conclusions: The prevalence of cardiac autonomic neuropathy, defined as an 
abnormality in two or more cardiac reflex tests, was low in these patients with 
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T1DM and was associated with a long duration of disease.  The presence of 
cardiac autonomic dysfunction does not appear to be a major influencing factor on 
the development of IAH supporting other  recent studies investigating this 
association (Olsen et al., 2016, Kamel et al., 2015).  Further epidemiological 
studies are required to establish the natural history of DAN and to identify 
patients at risk. 
3.2 Background 
Studies previously carried out to determine the relationship between IAH and 
DAN have been inconsistent and contradictory (Stephenson et al., 1996, Meyer et 
al., 1998, Ryder et al., 1990, Hepburn et al., 1990).  This is due to a previous lack 
of a standard accepted definition of DAN and the confounding factors of age, 
glycaemic control and duration of diabetes.   Baroreflex sensitivity (BRS), a 
measurement of how much control the baroreflex has on the heart, has not been 
considered in these earlier studies. 
  
The aim of this chapter is to investigate the possible association between IAH and 
DAN by comparing the prevalence of DAN in a group of subjects with T1DM and 
IAH, and a group with T1DM and normal awareness of hypoglycaemia.  DAN 
will be defined, as described in the consensus statement of 2010 (Tesfaye et al., 
2010), which provided an update on definitions and diagnostic criteria for DAN.  
Spectral analysis of HRV and BRS will be used to identify cardiac dysfunction or 
subclinical neuropathy and confounding factors of age, glycaemic control and 
duration of disease will also be assessed and compared. 
 
3.3 Methods 
The HypoCOMPaSS trial was a UK-based, multicentred, prospective randomised 
control trial (RCT).  The study aimed to optimise diabetes treatment in patients 
with IAH (Gold score ≥4) to prevent biochemical hypoglycaemia (BH) and 
restore awareness.  Each participant underwent detailed cardiac autonomic 
function testing during a pre-randomisation, 4 week run in period, completed 
before any intervention was undertaken.   
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A sub-study of the hypoCOMPaSS trial was then designed.  The aim of this sub-
study was to recruit a population of adults with T1DM and normal awareness of 
hypoglycaemia (Gold score <4) and compare the prevalence of cardiac autonomic 
neuropathy in the two populations.  The sub-study population were matched for 
age and duration of disease.  Detailed cardiac autonomic function testing was 
completed following the same protocol as in the main trial. 
 
The protocol for the hypoCOMPaSS trial and the hypoCOMPaSS sub-study are 
described in full in chapter two but the salient points are reported below.  The 
study protocol, participant information sheets and consent forms for both studies 
were approved by an independent research ethics committee.  Written informed 
consent was obtained from each participant. 
  
Recruitment 
Participants were recruited to the main hypoCOMPaSS trial between July 2010 
and June 2011 and to the sub-study between August 2012 and August 2014.  
Subjects were recruited to the main HypoCOMPaSS trial from five UK tertiary 
referral and academic hypoglycaemia centres: Bournemouth Diabetes and 
Endocrine Centre, Bournemouth; Adenbrooke’s Hospital, Cambridge; Newcastle 
Diabetes Centre, Newcastle upon Tyne; Derriford Hospital, Plymouth and 
Sheffield Teaching Hospitals, Sheffield.  Sub-study participants were recruited 
from Sheffield Teaching Hospitals.   
  
Cardiac autonomic function testing 
All participants underwent detailed screening cardiac autonomic function testing 
as described by Ewing (Ewing and Clarke, 1982) including the modifications 
suggested by O’Brien (O'Brien et al., 1986) in accordance with the latest 
consensus on the diagnosis of cardiac autonomic neuropathy (Tesfaye et al., 
2010).  Tests included heart rate response during deep breathing, one valsalva 
manoeuvre and heart rate and blood pressure response to standing.  Participants 
were asked to refrain from smoking and caffeine on the day of the tests and beta 
blockers were discontinued 48 hours prior to testing.  A period of three minutes of 
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rest preceded each test and testing was carried out in a darkened room where noise 
was kept to a minimum.   
 
Two five minute simultaneous ECG and continuous blood pressure recordings, 
using a Portapres device, were made to measure BRS and allow spectral analysis 
of heart rate variability (HRV).  During the first five minute recording, 
participants remained at rest, with spontaneous breathing and monitoring of the 
respiratory rate.  During the second recording participants were asked to pace 
their breathing at a rate of 15 breaths per minute whilst maintaining a normal tidal 
volume.  Results were compared to the O’Brien age adjusted normal ranges 
(O'Brien et al., 1986).   
 
Statistical analysis 
Data that followed an approximate normal distribution were summarized using 
mean (standard deviation (SD)) unless otherwise stated, whilst skewed data were 
summarized using the median (interquartile range).  Spectral HRV parameters 
were logarithmically transformed to approximate a normal distribution.  
Prevalence of DAN was compared using chi square test for independence.  
Potential confounding factors of age, duration of diabetes, sex and pre-existing 
micro- and macrovascular complications were examined using independent t test.  
The impact of duration of diabetes and the presence of DAN on symptomatic 
awareness of hypoglycaemia were further explored using a model of logistic 
regression. Awareness of hypoglycaemia was defined as the categorical outcome 
and DAN and duration of diabetes as predictor variables. Statistical analysis was 
performed with SPSS (version 22.0, IBM, Chicago, Illinois). A p-value ≤ 0.05 




A total of 110 participants with IAH (Gold score ≥4) were recruited to the main 
hypoCOMPaSS trial; six were excluded due to elevated C-peptide levels and eight 
withdrew from the study before randomisation.  Ninety six were randomised, all 
with c-peptide negative, (<50pmol/L in all except two:87; 103 pmol/L) T1DM.  
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Three participants were excluded from this sub-analysis due to incomplete 
autonomic function testing.   
 
A total of sixty four participants with normal awareness of hypoglycaemia (Gold 
score<4) were recruited to the hypoCOMPaSS sub-study.  Ten were excluded due 
to elevated C-peptide levels and three withdrew before completion of the study.  
Of the fifty one subjects included in this analysis, thirty nine were c-peptide 
negative (<50pmol/L) and eleven participants had a c-peptide above 50pmol/L but 
below the lower end of the local reference range (298pmol).   
 
Baseline characteristics for all participants are shown in table seven.  The mean 
gold score for participants with intact awareness of hypoglycaemia was two and 
for participants with IAH the mean gold score was five (independent t test 
p=<0.005).  The incidence of SH was higher in participants with IAH (median 4 
(7) in 12 months vs. 0 (0) p=<0.005). 
 
Participants with IAH had a significantly longer duration of disease compared to 
those with intact awareness (independent t test p=0.001).  The prevalence of 
retinopathy and neuropathy was similar between the two groups but participants 
with intact awareness of hypoglycaemia had a higher incidence of nephropathy.  
Participants with IAH had a higher incidence of macrovascular complications.  
There was no statistical difference in age between the two groups (p=0.06) and 




















Age (years) 45 (11) 49 (12)  0.066 
Sex (M/F) 22/29 35/58 0.64 
BMI  26 (4) 27 (1) 0.303 
Duration of diabetes 
(years) 
22 (11) 29 (12)  0.001 
HbA1c 69 (13)  66 (13)  0.182 
Insulin dose (units/kg) 0.7 (0.3) 0.6 (0.2) 0.073 
Gold score 2 (1)  5 (1)  <0.005 
SH in the last 12 
months 
0 (0)  4 (7)  <0.005 
HR (bpm) 71 (11) 71 (10) 0.206 
Systolic blood pressure 
(mmHg) 
131 (16) 131 (18) 0.989 
Diastolic blood 
pressure (mmHg) 
76 (9) 76 (11) 0.913 
Retinopathy  35 (69%) 58 (62%) 0.264 
Neuropathy 9 (17%) 16 (17%) 1 
Nephropathy 5 (10%) 4 (4%) 0.345 
Macrovascular disease 3 (6%) 12 (13%) 0.301 
Results given as mean (SD) except episode of SH where median (IQR) is given and for retinopathy, 
neuropathy, nephropathy and macrovascular disease prevalence which is given as actual number (%). 
Table 7 Baseline characteristics. 
 
The prevalence of definite DAN, defined as the presence of two or more abnormal 
cardiac reflex tests (Tesfaye et al., 2010) was similar in both participant groups, 
affecting four percent of participants with normal awareness of hypoglycaemia 
and five percent of those with IAH.  (Figure 8 and Table 8).  Seventy one percent 
of participants with intact awareness of hypoglycaemia had normal cardiac 
autonomic function tests compared to 80% of participants with IAH.   The 
prevalence of DAN was lower than expected in both participant groups.  A Chi-
square test for independence indicated no significant association between 
awareness of hypoglycaemia and cardiac autonomic function (p=0.37).  The 
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prevalence of abnormal BRS was higher in participants with IAH (Figure 9 and 
Table 8) but a Chi-square test for independence indicated no significant 
association between awareness of hypoglycaemia and abnormal BRS (p=0.64).  
Heart rate and measures of HRV were similar between the two participant groups.     
Cardiac autonomic function 





Heart rate 71 (11) 71 (10) 0.206 
SDRR 33 (18) 35 (20) 0.795 
RMSSD 24 (16) 23 (19) 0.955 
Log HF  2.0 (0.62) 1.9 (0.62) 0.081 
LF norm 0.63 (0.16) 0.66 (0.20) 0.001 
BRS  12 (6) 13 (16) 0.956 

























Results given as mean (SD) except BRS and cardiac autonomic function status which is given as actual 
number (%). 
Table 8 Results of cardiac autonomic function tests. 
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Figure 8 Prevalence of cardiac autonomic neuropathy in participants with intact and impaired awareness 
of hypoglycaemia. 
 
Figure 9 Prevalence of abnormal BRS in participants with intact and impaired awareness of 
hypoglycaemia. 
 
Figure ten shows cardiac autonomic status results when participants are divided 
into categories based on duration of diabetes.  This indicates that the prevalence of 
DAN increases with duration of diabetes.  However, chi-square test for 
independence, indicated no significant association between duration of disease 













Intact awareness IAH 
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Figure 10 Prevalence of cardiac autonomic neuropathy in participants with short, medium and long 
duration of disease. 
 
Direct logistic regression was performed to assess the impact of both cardiac 
autonomic function status and duration of diabetes on reported awareness of 
hypoglycaemia.  The model was statistically significant, χ2 (2, N=144) = 12.10, 
p=0.002, indicating that the model was able to distinguish between participants 
that reported IAH and those that did not.  The model explained between 8.1% 
(Cox and Snell R square) and 11.1% (Nagelkerke R squared) of the variance in 
awareness of hypoglycaemia and correctly classified 66% of cases.  Duration of 
diabetes made a statistically significant contribution to the model with an odds 
ratio of 1.06.  This indicates that for every year of disease the participants were 
1.06 times more likely to develop IAH or for each additional year of diabetes 
increases the odds of developing IAH by six percent (table 9).  The presence of 
DAN did not make a statistically significant contribution (table 9).  
 B S.E. Wald Df P value Odds 
Ratio 
95.0% C.I for Odds 
Ratio 
       Lower         Upper 
Presence 
of DAN 





0.05 0.02 10.59 1 0.01 1.06  1.02              1.09 
Constant -0.75 0.44 2.97 1 0.09 0.47  












<15 years 15-30 years >30 years 
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3.5 Conclusions 
The prevalence of DAN was low in participants with impaired (5%) and normal 
awareness of hypoglycaemia (4%).  The most commonly reported data evaluating 
the prevalence of DAN is from the Diabetes Control and Complications Trial 
(DCCT) and the follow up study, Epidemiology of Diabetes Interventions and 
Complications (EDIC).  In the DCCT (Pop-Busui et al., 2016), studying patients 
with T1DM of duration of 1-15years, prevalence of DAN was 9%.  This rose to 
31% in the EDIC, when researchers followed up 90% participants of the DCCT 
with duration of diabetes greater than 15 years.   
 
The reported prevalence of DAN varies depending on the cohort of patients 
recruited, tests used and the definition of DAN in each study.  In these studies 
cardiac autonomic neuropathy was evaluated by heart rate variability during deep 
breathing and the valsalva manoeuvre and diastolic blood pressure on standing.  
Cardiac autonomic neuropathy was defined as an abnormality in any one of these 
tests.  Applying the same diagnostic criteria to participants in this study 24% of 
participants would be classified as having cardiac autonomic neuropathy.  The 
DCCT and EDIC did not use age-related normal ranges for the cardiac reflex tests 
which were used in this study which may account for the reduction in prevalence 
of DAN in the subjects in the hypoCOMPaSS studies.   
 
The cardiac autonomic neuropathy seen in the hypoCOMPaSS studies was more 
advanced in participants with a longer duration of disease.  In 2010 Tesfaye et al 
(Tesfaye et al., 2010) reported on the updates regarding classification, definitions 
and diagnostic criteria of DAN.  The diagnostic criteria and staging of DAN are 
still being debated but the panel recommended that at least two abnormal HRV 
tests are required to confirm DAN and orthostatic hypotension would indicate 
more advanced cardiac autonomic neuropathy.  Based on these diagnostic criteria 
only 10% (14/144) of the total study population have cardiac autonomic 
neuropathy and all these participants had a duration of diabetes of greater than 15 
years.  Only two participants had cardiac autonomic neuropathy with orthostatic 
hypotension; one subject with IAH and a diabetes duration of 44 years and one 
subject with normal awareness of hypoglycaemia with a duration of diabetes of 23 
years. 
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IAH is associated with a long duration of disease and an increased incidence of 
SH.  Both participant groups had a mean duration of diabetes of greater than 20 
years but the participants with IAH had a significantly longer duration of disease 
despite efforts made to match participant groups (Table 8 p=0.001).  Direct 
logistic regression was performed to assess the impact of duration of diabetes on 
reported awareness of hypoglycaemia.  Duration of diabetes made a statistically 
significant contribution to the model and indicated that for each additional year of 
diabetes the odds of developing IAH increased by six percent (table 9).  Previous 
studies (Mokan et al., 1994) (Hepburn et al., 1990) have also consistently reported 
the association of IAH with a long duration of disease.  The study also confirms 
previous findings (Schopman et al., 2011) that participants with IAH (median 
4(7)) have significantly more episodes of SH than those participants with normal 
awareness of hypoglycaemia (0(0) p=<0.005). 
 
This study shows that IAH is not associated with an increased prevalence of DAN 
or abnormal BRS.  Seventy one percent of participants with normal awareness of 
hypoglycaemia had completely normal cardiac autonomic function tests in 
comparison to eighty percent of the impaired awareness group.  There was a 
slightly higher prevalence of abnormal BRS in the impaired awareness group but 
this did not reach statistical significance.  Historically DAN was described as the 
mechanism causing IAH but the data in the literature is conflicting (Stephenson et 
al., 1996, Meyer et al., 1998, Ryder et al., 1990, Hepburn et al., 1990).  More 
recently a study by Olsen and colleagues (Olsen et al., 2016) also concluded that 
IAH was not associated with autonomic neuropathy and a further study by Kamel 
et al (Kamel et al., 2015) has showed that reversal of hypoglycaemia unawareness 




The unexpected low prevalence of DAN in the study participants means that this 
study is underpowered, but increasing participant numbers, even significantly, is 
unlikely to change the study conclusions.  Power calculations for this study were 
based on a study by Hepburn and colleagues in 1990 (Hepburn et al., 1990) with a 
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prevalence of DAN of 37% in participants with normal awareness of 
hypoglycaemia and 67% in subjects with IAH.  The prevalence of cardiac 
autonomic neuropathy only differed by one percent between participants with 
IAH and normal awareness of hypoglycaemia, and therefore, it would be unlikely 
that increasing participant numbers would change the conclusions made.  
 
Other potential limitations of this study include the use of spontaneous breathing 
during ECG recordings and differences in geographical distributions between the 
two participant groups. It is recommended that heart rate variability should be 
measuring when participants are undergoing paced breathing at a rate of 15 
breaths per minute.  As participants were being investigated by different clinical 
teams in different parts of the country it was felt that spontaneous breathing would 
limit inter-investigator differences.  All participants had their respiratory rate 
measured to ensure that this was not fewer than 10 breaths per minute.   
 
Further consideration should be given to other measures of autonomic 
dysfunction.  This study used cardiac reflex tests to assess autonomic function and 
did not utilise other tests of the autonomic nervous system including tests of 
papupillomotor or sudomotor function.  Tests for cardiac autonomic function are 
simple, quick, non-invasive and can be done at the bedside.  Testing was limited 
to these tests to allow the tests to be done in each centre and then analysed in one 
site to improve reliability.    
 
Final conclusions 
The presence of cardiac autonomic neuropathy is not associated with or an 
influencing factor in the development of IAH.  IAH is associated with a long 
duration of diabetes and this is an independent risk factor for the development of 
reduced symptomatic awareness of hypoglycaemia.   The prevalence of DAN is 
lower than previously reported and illustrates the need for further epidemiological 
studies to investigate DAN in patients with T1DM.  It is an important 
complication of diabetes because of the increased risk of death but it is one of the 
least studied.  Further work is also required to document the natural history of the 
autonomic neuropathy particularly the potential progressive nature of the 
condition in order to develop potential treatments in the future.       
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Chapter 4: The Effect of Diabetic Autonomic Neuropathy on 
the Ability to Improve Awareness of Hypoglycaemia in Type 
One Diabetes Mellitus. 
4.1 Abstract 
Objectives:  Impaired awareness of hypoglycaemia (IAH), affects 25% of 
patients with type one diabetes (T1DM), and increases the risk of episodes of 
severe hypoglycaemia (SH).  IAH can potentially be reversed by complete 
avoidance of biochemical hypoglycaemia (BH), but treatment programmes are 
time consuming, expensive and a proportion of patients will not respond.  
Traditionally diabetic autonomic neuropathy (DAN) was described as the 
underlying mechanism causing IAH.  Studies examining the relationship have 
shown it is unlikely to be the primary cause but the relationship between the two 
entities remains undefined.  The aim of this study was to examine the effect of 
DAN on the ability to reverse IAH. 
Methods:  Eighty three participants with T1DM and IAH (Gold score ≥ 4) were 
recruited to the hypoCOMPaSS trial; a 24 week 2x2 factorial randomised 
controlled trial.  All participants underwent screening cardiac autonomic function 
testing prior to study intervention to ascertain the presence or absence of DAN.  
All received comparable education and support, aimed at avoiding BH, and 
improving symptomatic awareness of hypoglycaemia.  Participants were grouped 
depending on their cardiac autonomic status, and changes in gold score in the 
different groups were compared.    
Results:  The prevalence of DAN was low with only 5/83 (6%) participants 
having definite cardiac autonomic neuropathy, defined as the presence of two or 
more abnormal cardiac reflex tests.  All patient groups including those with 
normal cardiac autonomic function, possible or early cardiac autonomic 
dysfunction and definite cardiac autonomic dysfunction showed a mean 
improvement in Gold score ≥1.  There was a greater reduction in gold score in 
participants that were younger and had a shorter duration of disease. 
Conclusion: IAH can be improved in patients with T1DM, and a long duration of 
disease, with and without the presence of cardiac autonomic dysfunction.  This 
suggests that autonomic neuropathy is not a prime driver of the syndrome of IAH.  
The lower than expected prevalence of DAN in this study indicate a need for up to 
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date epidemiological studies to establish the prevalence of DAN in T1DM with a 
short and long duration of disease. 
4.2 Background 
Impaired awareness of hypoglycaemia (IAH) is the loss of the autonomic 
symptoms of hypoglycaemia before neuroglycopenia occurs.  There is evidence 
that the clinical syndrome of IAH can improve, and can at least be partially 
reversed, by complete avoidance of biochemical hypoglycaemia (BH) (Fanelli et 
al., 1993b, Cranston et al., 1994).  Studies investigating the reversibility of IAH 
often exclude patients with DAN but a small study by Fanelli and colleagues 
(Fanelli et al., 1997) showed that DAN did impede reversibility to a degree.     
 
The hypoCOMPaSS (Comparison of Optimised MDI versus Pumps with or 
without Sensors in Severe Hypoglycaemia) Trial was a UK-based, multicentred, 
prospective randomised controlled trial (RCT).  The aim was to optimise diabetes 
treatment in patients with IAH, to prevent BH, and restore symptomatic 
awareness of hypoglycaemia.  In this sub-analysis we investigate if cardiac 
autonomic status, and the presence of clinical or subclinical autonomic 
neuropathy, adversely affects a patient’s ability to respond to and reverse the 
clinical syndrome of IAH.   
 
Participants of the hypoCOMPaSS trial underwent detailed cardiac autonomic 
function testing in the wash in period, before randomisation, and before any 
treatment intervention.  The participants underwent the six month treatment 
period and cardiac autonomic function testing was repeated.  Participants were 
divided into groups depending on their cardiac autonomic function status as 
defined by the latest consensus published by the Toronto working group (Tesfaye 
et al., 2010).  Changes in Gold score were compared between groups with 
different cardiac autonomic status. 
4.3 Methods 
Participants with T1DM and IAH (gold score≥ 4) were recruited to the 
HypoCOMPaSS trial. The protocol for the hypoCOMPaSS trial is described in 
full in chapter two but the salient points are reported below.   
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Cardiac autonomic function testing 
All participants underwent detailed screening cardiac autonomic function testing 
as described by Ewing (Ewing and Clarke, 1982) including the modifications 
suggested by O’Brien (O'Brien et al., 1986) in accordance with the latest 
consensus on the diagnosis of cardiac autonomic neuropathy (Tesfaye et al., 
2010).  Tests included heart rate response during deep breathing, one valsalva 
manoeuvre and heart rate and blood pressure response to standing.  Participants 
were asked to refrain from smoking and caffeine on the day of the tests and beta 
blockers were discontinued 48 hours prior to testing.  A period of three minutes of 
rest preceded each test and testing was carried out in a darkened room where noise 
was kept to a minimum.   
 
Two five minute simultaneous ECG and continuous blood pressure recordings, 
using a Portapres device, were made to measure baroreflex sensitivity (BRS) and 
allow spectral analysis of heart rate variability (HRV).  During the first five 
minute recording, participants remained at rest, with spontaneous breathing and 
monitoring of the respiratory rate.  During the second recording participants were 
asked to pace their breathing at a rate of 15 breaths per minute whilst maintaining 
a normal tidal volume.  Results were compared to the O’Brien age adjusted 
normal ranges (O'Brien et al., 1986).   
 
HypoCOMPaSS Intervention 
A web-based system was used to randomly allocate participants on an equal 
allocation basis, stratified by baseline HbA1c (<64mmol/L and ≥ 64mmol/L) and 
study centre, to one of four treatment arms: multiple daily injections (MDI) with 
self monitoring of blood glucose (SMBG), MDI with SMBG and RT-CGM, CSII 
with SMBG, and CSII with SMBG and RT-CGM.  The primary goal of insulin 
dose titration throughout the 24 week RCT period was the absolute avoidance of 
all glucose levels less than 4 mmol/L as determined by RT-CGM and SMBG.   
 
Prior to randomisation, all participants underwent a standardised education 
session on an individual or small group basis.  Discussions were facilitated 
focusing on avoidance of BH and early detection of all blood glucose levels less 
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than 4 mmol/L.  The aim of the session was prevention of progression to 
significant hypoglycaemia while maintaining overall glycaemic control.  
Participants were advised to treat all glucose levels less than 4 mmol/L with 15g 
of carbohydrate with repeat SMBG every 15 min until glucose rose above 4 
mmol/L and to consider prospective insulin dose reduction.  
 
During the 24 week intervention participants received at least weekly contact 
from a health care professional for advice regarding insulin titration.  All 
participants received an insulin pump (Paradigm Veo insulin pump; Medtronic), 
whether allocated insulin via CSII (aspart) or MDI (aspart/glargine), to allow the 
benefit of direct transmission of SMBG levels to a bolus calculator.  Participants 
recorded episodes of SH prospectively. 
 
Statistical analysis 
Data that followed an approximate normal distribution were summarized using 
mean (standard deviation (SD)) unless otherwise stated, whilst skewed data were 
summarized using the median (interquartile range).  Spectral HRV parameters 
were logarithmically transformed to approximate a normal distribution.  
Following the 24 week RCT a comparison of baseline and end HbA1c, insulin 
dose, gold score and number of episodes of SH was completed using paired t test.  
Participants were divided by cardiac autonomic status, and change in gold score 
between groups, was compared using chi square test.  Potential confounding 
factors of age, duration of diabetes, sex and pre-existing micro- and 
macrovascular complications were examined using one way ANOVA.  Statistical 
analysis was performed with SPSS (version 22.0, IBM, Chicago, Illinois). A p-
value ≤ 0.05 was deemed statistically significant.  
4.4 Results 
Participants 
A total of 110 participants with IAH (Gold score ≥4) were recruited to the 
hypoCOMPaSS trial.  Six participants did not meet C-peptide inclusion criteria, 
and 8 withdrew from the study before randomisation.  Ninety six were 
randomised, all with long-standing (mean duration 29 years), c-peptide negative, 
(<50pmol/L in all except two:87; 103 pmol/L) T1DM.  Six participants did not 
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adhere to their randomised treatment but were included in the intention-to-treat 
analysis.   
 
The results from the hypoCOMPaSS trial were reported in 2014 (Little et al., 
2014) and showed that hypoglycaemia awareness can be improved, and recurrent 
SH prevented, in long standing type 1 diabetes and IAH.  This was through 
strategies deliverable in routine clinical practice, targeted at rigorous avoidance of 
BH without relaxation of overall control.  When provided with equal education 
and attention, equivalent biochemical outcomes and reduction in fear of 
hypoglycaemia were attained with conventional MDI and SMBG regimens 
compared with CSII and CGM-RT.  Treatment satisfaction was higher in CSII 
users. 
 
A total of eighty three subjects are included in this sub-analysis.  Of the ninety six 
subjects that were randomised in the hypoCOMPaSS trial, nine were excluded 
from this analysis, due to not completing the six month treatment period.  A 
further two participants were excluded because of incomplete end of study 
questionnaires which included Gold score assessment.  A further two subjects 
were excluded due to incomplete cardiac autonomic function testing.   
 
Baseline characteristics are shown in table ten.  The incidence of severe 
hypoglycaemia was high with a mean rate of episodes of 9 (13) in the twelve 
months prior to the study (median 4 [2.5] Range 0 to >50 episodes).  Eight 
participants reported no severe episodes in the year prior to the study and five 
reported greater than 50 episodes in the previous 12 months.     
 
Cardiac autonomic function 
All participants underwent detailed cardiac autonomic function testing.  Definite 
DAN was defined as the presence of two or more abnormal cardiac reflex tests 
(Tesfaye et al., 2010).    The results are presented in table eleven.  Eleven 
participants had possible or early cardiac autonomic neuropathy and five 
participants had definitive cardiac autonomic neuropathy. 
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Baseline characteristics n=83 
Age (years) 48 (12)  
Sex (M/F) 31/52 
BMI  27 (5) 
Duration of diabetes (years) 29 (13) 
HbA1c 66 (13)  
Insulin dose (units/kg) 0.7 (0.2) 
Gold score 5 (1)  
SH in the last 6 months 5 (10)  
SH in the last 12 months 9 (13)  
HR (bpm) 72 (10) 
Systolic blood pressure (mmHg) 131 (18) 
Diastolic blood pressure (mmHg) 76 (11) 
Retinopathy  52 (63%) 
Neuropathy 14 (17%) 
Nephropathy 3 (4%) 
Macrovascular disease 11 (13%) 
Results given as mean (SD) except for retinopathy, neuropathy, nephropathy and macrovascular disease 
prevalence which is given as actual number (%). 
 
Table 10 Participant characteristics.  
 n=83 
Heart rate 72 (10) 
SDRR 34 (20) 
RMSSD 23(20) 
Log HF  2.5 (1.4) 
LF norm 0.61 (0.23) 
BRS (n=32) 10.3 (5.4) 
Cardiac autonomic function status 











Table 11 Screening cardiac autonomic function results 
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Study outcomes 
The results of the hypoCOMPaSS trial have been published in full (Little et al., 
2014).  The population in this sub analysis showed similar improvements in 
hypoglycaemia awareness and reduction in episodes of SH (table 12).  Glycaemic 
control, as assessed by HbA1c, did not deteriorate and insulin requirements 
reduced (table 13). 






















Data are mean (SD), Median [interquartile range]. *paired t test between week 24 end point and baseline. 
Table 12 SH and hypoglycaemia awareness in study population at baseline and 24 week end point (n=78). 
 Baseline Week 24 P value* 
HbA1c 66 (13) 65 (11) 0.40 
Insulin  
(units per kg) 
0.7 (0.3) 0.5 (0.2) <0.0005 
Data are mean (SD) *paired t test between week 24 end point and baseline. 
Table 13 HbA1c and insulin doses in study population at baseline and 24 week endpoint. 
The presence of cardiac autonomic neuropathy did not impede the ability of 
participants to improve hypoglycaemia awareness defined as the reduction of gold 
score ≥1 (figure 11).  A Chi-square test for independence indicated no significant 
association between cardiac autonomic function status and a reduction in gold 
score of ≥1 (p=0.743).  The mean reduction in gold score was -1.2 (1.6).  The 
greatest reduction was seen in participants with early DAN with a mean reduction 
of 1.36 (1.5) and the smallest reduction was seen in participants with definite 
DAN (1.0 (1.2)).  Participants that had normal cardiac autonomic function had a 
mean reduction in gold score of 1.2 (1.7).  Participants that had normal BRS 
showed a reduction in gold score of -1.45 and those with abnormal BRS showed a 
greater mean reduction in gold score of- 1.8.   
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Figure 11 The effect of cardiac autonomic status on the improvement of Gold score. Chi-square test for 
independence indicated no significant association between cardiac autonomic function status and a 
reduction in gold score of ≥1 (p=0.743) 
 
Participants aged less than 30 years had a greater improvement in gold score 
compared to participants aged over thirty years (p=0.017) (Figure 12).  Nine 
participants were aged under 30 and had a mean reduction in gold score of 2 (0.9).  
Seventy four participants were aged over 30 years and had a mean reduction in 
gold score of 1.1 (1.6).   




Figure 12 Effect of age on Gold score reduction (p=0.017). 
 
Participants with shorter duration of diabetes (<30 years) had a greater 
improvement in gold score in comparison to those with a longer duration of 
disease (figure 13).  Forty seven participants had a duration of diabetes of less 
than 30 years and had a mean reduction in gold score of -1.3 (median reduction of 
-2.0[2]).  Participants with a duration of greater than 30 years had a mean 
reduction of -0.9 (1.6) and median reduction of -1.0 [2].   
 




Figure 13 Effect of duration of disease on Gold score reduction. 
 
Sex and the presence of other complications of diabetes did not impede the 
reduction in hypoglycaemia and the improvement in Gold score seen in 
participants.  Median change in Gold score in both male and female participants 




This study confirms previous observations that IAH in T1DM is associated with 
an older age and a long duration of disease (Graveling and Frier, 2010).  It is also 
associated with a high incidence of recurrent episodes of severe hypoglycaemia 
(Gold et al., 1994).  The prevalence of both microvascular and macrovascular 
complications was also similar to previously reported levels in participants with a 
long duration of disease (Nathan et al., 2009). 
 
The prevalence of DAN (defined as an abnormality in two or more cardiac reflex 
tests) in this group of subjects with T1DM and a long duration of disease was low.  
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The prevalence of DAN reported in other published studies varies depending on 
the cohort of patients studied, the diagnostic tests used and the diagnostic criteria 
adhered to (Vinik et al., 2003).  A study by Ziegler et al recruited from 22 
diabetes centres in Germany, Austria and Switzerland  and reported that 25.3% of 
subjects had abnormalities in two or more cardiac reflex tests (Ziegler et al., 
1992).  This study was reported in 1992, 19 years prior to the hypoCOMPaSS 
study, and before intensive insulin therapy had been fully established, and may 
indicate a change in the prevalence of DAN in patients with T1DM.   
 
More recently the DCCT and, then the follow up study, Epidemiology of Diabetes 
Interventions and Complications (EDIC) reported the prevalence of DAN to be 
9% and 31% respectively (Pop-Busui et al., 2016).  In these studies DAN was 
defined as an abnormality in one cardiac reflex test.  Applying the same 
diagnostic criteria in this study 19% of participants would be classified as having 
DAN.  
 
The hypoCOMPaSS study has shown that improvement in symptomatic 
awareness of hypoglycaemia, with a reduction in episodes of SH,  is possible in 
patients with long standing T1DM without deterioration in glycaemic control 
(Little et al., 2014).  In this cohort of patients mean Gold score reduced from 5(1) 
to 4(2) and the proportion of patients affected by SH reduced from 92% to 6%.  
There was a greater reduction in Gold score in those participants that were 
younger and those with a shorter duration of disease confirming previous 
observations (Fannelli et al., 1994).   
 
The presence of DAN did not impede the ability of participants to improve their 
awareness of hypoglycaemia in this study.  The majority of previous studies 
investigating the ability to reverse IAH exclude participants with autonomic 
neuropathy with the exception of a study by Fanelli and colleagues (Fanelli et al., 
1997) and more recently by Kamel et al (Kamel et al., 2015).  Fanelli and 
colleagues designed a 6 month treatment period aimed at avoiding BH in patients 
with T1DM and DAN to improve their symptomatic awareness of hypoglycaemia.  
The participants (eight without DAN and thirteen with DAN) in this study 
underwent a hypoglycaemic clamp study and symptomatic and adrenergic 
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responses to hypoglycaemia improved in participants with and without DAN after 
the 6 month treatment period.  The improvements observed were less in subjects 
with abnormal cardiac autonomic function.  Kamel et al reviewed five patients 
with T1DM and DAN undergoing either islet cell or whole pancreas transplants.  
Improvement in hypoglycaemia awareness was seen all patients after transplant 
despite abnormal cardiac function tests. 
 
Younger participants and those with a shorter duration of diabetes had greater 
improvements in gold score compared to participants that were older and had a 
longer duration of disease.  Fanelli et al (Fanelli et al., 1993b) reported that IAH 
was reversible in patients with short duration diabetes in 1993 and then extended 
this observation to included participants with a long duration of disease (>15 
years) in 1994 (Fannelli et al., 1994).  They found that participants with a longer 
duration of disease showed improvement in hypoglycaemia awareness but the 
recovery of responses was inversely correlated with duration of disease.  There 
was no clear underlying cause for the reduction in improvement in these patients 
and the authors specifically commented that patients did not have overt diabetic 
autonomic neuropathy.  There is little comment in the literature regarding the 
impact of age in relation to the reversibility of hypoglycaemia unawareness, 
presumably due to the difficultly in separating this from duration of disease.  
Investigating the relationship between age and duration of diabetes in this group 
of subjects using the Pearson product-moment correlation coefficient revealed a 
strong positive relationship (r=0.508). 
 
Limitations 
The main limitations of this study were the unexpected low prevalence of DAN 
and that testing was limited to cardiac autonomic function testing.  This study 
only used cardiac reflex tests to assess autonomic function and did not utilise 
other tests of the autonomic nervous system including tests of pupillomotor or 
sudomotor function.  Tests for cardiac autonomic function are simple, quick, non-
invasive and can be done at the bedside.  Testing was limited to these tests to 
allow the tests to be done in each centre and then analysed in one site to improve 
reliability.   
 




IAH can be improved in participants with a long duration of disease, and in those 
with and without cardiac autonomic neuropathy.  Since the awareness of 
hypoglycaemia can be improved, despite the presence of autonomic dysfunction, 
it suggests that autonomic neuropathy is not a prime driver of the syndrome.  The 
prevalence of DAN was lower than previous studies and up to date 
epidemiological studies are required to establish the prevalence of DAN in 
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Chapter 5: Cardiac Autonomic Regulation During 
Experimental Hypoglycaemia in Type One Diabetes with 
Impaired Awareness of Hypoglycaemia. 
5.1 Abstract 
Aims: Impaired awareness of hypoglycaemia (IAH) and classical diabetic 
autonomic neuropathy (DAN) have been respectively shown to reduce the 
symptomatic and autonomic counter-regulatory responses to hypoglycaemia 
(Heller et al., 1987, Bottini et al., 1997).  These exploratory studies investigated 
the effect of experimental hypoglycaemia on cardiac autonomic regulation in 
patients with type 1 diabetes (T1DM) and IAH.       
Methods:  Eight participants with T1DM and IAH (Gold score ≥4), ten with 
T1DM and intact awareness of hypoglycaemia (Gold score<4) and ten without 
diabetes underwent a stepped hyperinsulinaemic hypoglycaemic clamp study.  
Glucose was held at 5mmol/l at time 20 minutes and reduced step-wise to a nadir 
of 2.4mmol/l at time 180 minutes.  Heart rate and heart rate variability were 
measured during each glucose step. 
Results: Participants with IAH had a longer duration of diabetes and lower 
symptom scores and metanephrine responses to hypoglycaemia than participants 
with intact awareness of hypoglycaemia.  Baseline cardiac autonomic function 
tests were normal in all participants but baseline heart rate was higher, and vagal 
tone lower, in participants with diabetes compared to participants without 
diabetes.  During hypoglycaemia participants without diabetes showed an increase 
in heart rate, with associated vagal withdrawal, that recovered to baseline by the 
end of the study.  Participants with T1DM and intact awareness of hypoglycaemia 
showed a gradual increase in heart rate and corresponding vagal withdrawal 
without evidence of recovery.  Participants with IAH showed little changes in 
heart rate or vagal tone during hypoglycaemia. 
Conclusions:  Participants with diabetes had evidence of subclinical cardiac 
autonomic neuropathy with an elevated heart rate and reduced vagal tone despite 
normal cardiac reflex tests.  Heart rate response to hypoglycaemia was time 
dependent and differed according to self reported awareness of hypoglycaemia.  
Participants with IAH showed smaller changes in heart rate and HRV during 
hypoglycaemia, possibly due to a failure of autonomic responses to 
hypoglycaemia rather than true classical DAN.  This is likely to be due to 
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dysfunction associated with a long duration of disease and reduced autonomic 
responses following repeated episodes of hypoglycaemia.    
 
5.2 Background 
Intensive insulin therapy is used in type one diabetes mellitus (T1DM) to avoid 
the long term complications of the disease.  Impaired awareness of hypoglycaemia 
(IAH) is an acquired complication of insulin therapy whereby the ability to detect 
the onset of hypoglycaemia is diminished or absent. The aim of these exploratory 
studies was to document the effect of hypoglycaemia on cardiac autonomic 
function in participants with T1DM and intact and impaired awareness of 
hypoglycaemia.  These results will be compared to a group of volunteers without 
diabetes.   
5.3 Methods 
The hypoCOMPaSS (Comparison of Optimised MDI versus Pumps with or 
without Sensors in Severe Hypoglycaemia) Trial was a UK-based, multicentred, 
prospective, randomised controlled trial (RCT).  All eligible participants were 
invited to undergo a stepped hyperinsulinaemic hypoglycaemic clamp study 
before and after the 6 month intervention period.  A sub-study was then designed 
to recruit a control population to compare to the main hypoCOMPaSS 
population.   
 
The protocol for the main hypoCOMPaSS trial and hypoCOMPaSS sub-study are 
described in full in chapter two but the salient points are reported below.   
 
Participants 
Eight participants with IAH recruited to the HypoCOMPaSS trial from Sheffield 
Teaching Hospitals NHS Foundation Trust and Newcastle upon Tyne NHS 
Foundation Trust underwent a pre-treatment hyperinsulinaemic hypoglycaemic 
clamp study. Ten participants with T1DM and intact awareness of hypoglycaemia 
and ten participants without diabetes were recruited as a control population.   
 
Cardiac autonomic function testing 
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All participants underwent detailed screening cardiac autonomic function testing 
as described by Ewing (Ewing and Clarke, 1982) including the modifications 
suggested by O’Brien (O'Brien et al., 1986) in accordance with the latest 
consensus on the diagnosis of cardiac autonomic neuropathy (Tesfaye et al., 
2010).  Tests included heart rate response during deep breathing, one valsalva 
manoeuvre and heart rate and blood pressure response to standing.  Results were 
compared to the O’Brien age adjusted normal ranges (O'Brien et al., 1986).   
 
Two five minute ECG and continuous blood pressure recordings, using a 
Portapres device, were made to measure baroreflex sensitivity (BRS) and allow 
spectral analysis of heart rate variability (HRV).  During the first five minute 
recording, participants remained at rest, with spontaneous breathing and 
monitoring of the respiratory rate.  During the second recording participants were 
asked to pace their breathing at a rate of 15 breaths per minute whilst maintaining 
a normal tidal volume.      
 
Statistical analysis 
Data that followed an approximate normal distribution were summarized using 
mean (standard deviation (SD)) unless otherwise stated.  Skewed data were 
summarized using the median (interquartile range).  Spectral HRV parameters 
were logarithmically transformed to approximate a normal distribution.   
 
Changes in metanephrines were tested using analysis of covariance (ANCOVA).  
To compare symptom scores during the clamp, area under the curve was 
calculated for each person, and then analysis of variance (ANOVA) was used to 
test for a difference in the mean area under the curve.  Differences between mean 
heart rates of each group were calculated using a mixed effects repeated measures 
model.  Heart rate at T60, T100, T140 and T180 were defined as dependent 
variables and heart rate at T20 independent with a fixed factor for time and for 
patient group with an interaction term for time and group.  Post hoc analysis was 
completed with the Holm procedure.   
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Glucose thresholds for the release of metanephrine was defined as the measured 
glucose at the time of onset of a sustained (≥2 successive time points) increase in 
hormone concentrations ≥ 2SD above the mean baseline measurements 
(Choudhary et al., 2009).  Thresholds for the increase in total, autonomic and 
neuroglycopenic symptoms were determined as the measured glucose level at 
which the symptom score increased ≥ 2 over baseline on two consecutive 
assessments (Choudhary et al., 2009). Where this threshold was not reached, the 
lowest measured glucose for the individual was used as the threshold for that 
person (Choudhary et al., 2009). Statistical analysis was performed with SPSS 




A total of eight participants with T1DM and IAH (gold score ≥4), ten with T1DM 
and intact awareness of hypoglycaemia (gold score<4) and ten participants 
without diabetes are included in this analysis.  Baseline participant characteristics 
are shown in table fourteen. Participants with IAH were older than the participants 
in the two control groups, although the differences did not reach statistical 
significance (p=0.26).  There were a higher proportion of female participants in 
the participants without diabetes and intact awareness and the participants without 
diabetes had a higher BMI. 
Participants with diabetes had a long duration of disease with a mean average 
length of disease being over twenty years in both groups.  Subjects with IAH had 
a non-significant longer duration of disease, (p=0.09) and glycaemic control was 
similar within the groups with diabetes.  There was an expected increased 
incidence of SH in participants with IAH, with an average incidence of 3.5 
episodes in the six months prior to the study.  There were no reported episodes of 
SH in the participants with intact awareness in the 12 month time period prior to 
enrolment in the study.   
Screening cardiac autonomic function tests showed that no participants had 
clinically significant cardiac autonomic neuropathy (table 15).  This was based on 
the definition of DAN, as having two or more abnormal cardiac reflex tests 
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(Tesfaye et al., 2010).   Average heart rate was higher and HRV was lower in the 
participants with diabetes (table 15).  The prevalence of retinopathy was high, 
corresponding to the increased risk with a longer duration of disease (Yau et al., 
2012), and the prevalence of peripheral neuropathy was between 10 and 20%.  
Participants were excluded if there was any evidence of nephropathy or 
macrovascular disease to ensure safety during the clamp studies.   
 








Age in years 38 (17) 41 (20) 48 (18) 0.26 
Sex (Male: Female) 3:7 4:6 4:4 0.69 




30.3 (8.1) 25.3 (2.1) 24.3 (2.5) 0.041 
Duration of 
diabetes in years 
N/A 21 (11) 31 (19) 0.09 









last 6 months 
N/A 0 3.5 (11.4) 0.02 
Heart rate (beats 
per minute) 
69 (11) 74 (9) 78 (10) 0.058 
Systolic blood 
pressure (mmHg) 
132 (18) 131 (13) 131 (11) 0.98 
Diastolic blood 
pressure (mmHg) 
83 (17) 78 (4) 76 (8) 0.38 
Retinopathy 0 7/10 (70%) 5/8 (63%) 1 
Peripheral 
neuropathy 
0 2/10 (20%) 1/8 (13%) 1 
 
Nephropathy 0 0 0  
Macrovascular 
disease 
0 0 0  
Results given as mean (standard deviation) except for age, duration of diabetes and SH where median 
(interquartile range) are given.  Retinopathy, peripheral neuropathy, nephropathy and macrovascular disease 
are number of patients/n (%). 
Table 14 Participant characteristics at screening visit 1. 













Heart rate  
(beats per minute) 
62 (7) 70 (12) 76 (14) 0.058 
SDRR 
(milliseconds) 
61 (29) 34 (12) 34 (23) 0.025 
RMSSD 50.6 24.9 27.2 0.017 
HF power 2.7 (0.5) 2.2 (0.4) 2.3 (0.4) 0.054 
LF norm 0.6 (0.1) 0.6 (0.2) 0.6 (0.3) <0.001 
































Table 15 Cardiac autonomic function test results. 
 
Blood glucose 
Arterialised blood glucose during the clamp studies are shown in figure fourteen.  
Starting blood glucose levels were higher in the participants with intact awareness 
in comparison to the other two groups (Without diabetes 5.84mmol/l, intact 
awareness 8.45mmol/l, IAH 6.35mmol/l).  At 200 minutes (T200) blood glucose 
in all three groups was under 3mmol/l (Without diabetes 2.62mmol/l, intact 
awareness 2.51mmol/l, IAH 2.44mmol/l).      
July 2018 Page 97 
 
 
Figure 14 Arterialised blood glucose during stepped hypoglycaemic clamp studies. 
 
Symptom scores 
Participants with IAH reported lower symptom scores at the onset of 
hypoglycaemia (time 100 minutes (T100)) (figure 15) in comparison to 
participants with intact awareness.  This difference was maintained until the end 
of the studies, although the difference between the groups did not meet statistical 
significance (p=0.231).  Total symptom thresholds developed at similar glucose 
concentrations (IAH 2.74, intact awareness 2.74 and without diabetes 2.86) but 
thresholds were not reached in three of the eight (38%) participants with IAH.   
Autonomic symptoms developed at a lower glucose in participants with IAH 
(2.55) in comparison to participants with diabetes with intact awareness (2.73) 
and in the participants without diabetes (2.85).    When reviewing autonomic 
symptom scores, glucose thresholds were only reached in three of the eight 
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.   
Figure 15 Mean symptom scores during hypoglycaemic clamp studies. 
 
Biochemical markers 
Plasma metanephrine increased in all groups between baseline and at time 200 
minutes, but the increase seen in participants with IAH was less in comparison to 
the control groups (table 16).  Using analysis of co-variance, adjusting for 
baseline, there was a statically significant difference between the groups 
(p=0.004).  Post hoc analysis showed the differences were statistically significant 
between the groups without diabetes and groups with diabetes (table 16).  Mean 
glucose thresholds for metanephrine release was 2.67 mmol/l in participants with 
IAH, 2.92 in participants with intact awareness and 3.29mmol/l in participants 
without diabetes.  Glucose threshold for the release of plasma metanephrines was 
not reached in five (63%) of the participants with IAH during the hypoglycaemic 














































Plasma metanephrines (pg/mL)     
Baseline (Glucose 5.0mmol/l) 175 213 200  
200 minutes (Glucose 2.4 mmol/l) 
 




Cortisol (nmol/L)     
Baseline (Glucose 5.0mmol/l) 220 317 311  
200 minutes (Glucose 2.4 mmol/l) 788 767 582  
Growth Hormone (ng/mL)     
Baseline (Glucose 5.0mmol/l) 0.4 1.9 5.7  
200 minutes (Glucose 2.4 mmol/l) 15.3 19.8 21.3  
Potassium (mmol/l)     
Baseline (Glucose 5.0mmol/l) 3.8 3.8 4.2  
200 minutes (Glucose 2.4 mmol/l) 3.1 3.3 3.7  
Using analysis of co-variance, adjusting for baseline, there was a statically significant difference between the 
groups (p=0.004).  Post hoc analysis showed the differences were statistically significant between the groups 
without diabetes and groups with diabetes. 
Table 16 Change in biochemical markers during the clamp studies. 
 
Heart rate 
Baseline heart rate, at T20, was higher in participants with diabetes (Table 17).  
Participants without diabetes had the lowest mean baseline heart rate of 65bpm.  
The highest mean baseline heart rate was seen in participants with IAH (79bpm).  
Participants with T1DM and intact awareness of hypoglycaemia had a mean 
baseline heart rate of 72bpm.   
 
Heart rate response to hypoglycaemia was different in the three groups (figure 
16).  An increase in heart rate was observed in participants without diabetes with 
recovery to below baseline by time 180 minutes (T180).  Participants with T1DM 
and intact awareness showed a gradual increase in heart rate without evidence of 
recovery by T180.  The participants with IAH showed a non-sustained brief 
increase in heart rate.  A repeated measures model using heart rate at T20 as an 
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independent variable showed that the difference in heart rate changes over time.  
At T180 the difference between the participants without diabetes and the groups 
with diabetes reaches statistical significance (table 17).  
 











IAH P value 
20 5 65 (12) 72 (11) 79 (14)  
60 3.8 64 (11) 74 (11) 81 (13)  
100 3.4 69 (10) 78 (12) 84 (16)  
140 2.8 69 (10) 79 (9) 83 (17)  





Values given as mean (SD).  A repeated measures model using heart rate at T20 as an independent variable 
showed that the difference in heart rate changes over time.  At T180 the difference between the participants 
without diabetes and the groups with diabetes reaches statistical significance. 
Table 17 Heart rate (bpm) during the clamp study. 
  
Spectral analysis results 
HF power, or vagal tone, at baseline (T20), was higher in the participants without 
diabetes compared to the groups with diabetes (figure 17).  Baseline LFnorm 
showed the inverse of the HF results (figure 17) and as LFnorm reflects both 
parasympathetic and sympathetic contribution, the differences seen in LFnorm is 
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HF power and LFnorm response to hypoglycaemia differs between the three 
participant groups.  Participants without diabetes showed a reduction in vagal tone 
during early hypoglycaemia which recovered by T180.  Participants with intact 
awareness of hypoglycaemia showed gradual vagal withdrawal without signs of 
recovery.  Participants with IAH showed little change in HF power.    
 
The participants with IAH showed a reduction in LFnorm indicating a possible 
reduction in sympathetic tone during hypoglycaemia.  Participants with intact 
awareness and without diabetes show an increase in LF norm during the clamp. 
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Participants Without diabetes Intact awareness IAH 
HR 
T20    


























































Table 18 Changes in HR and HRV between T20 and T180 (* p<0.05). 
 
Blood pressure and baroreceptor sensitivity 
Figures eighteen and nineteen illustrate the changes in systolic blood pressure and 
BRS during the clamp studies.  There was little change in systolic blood pressure 
during the clamp study but slight reductions were seen in the participants without 
diabetes and IAH.  A reduction in BRS was seen in the participants without 
diabetes which recovered to baseline by T180.  There was little changes seen in 
BRS in participants with diabetes.   
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Figure 19 Change in BRS during the clamp studies. 
 
Paired clamps 
Five participants that underwent a baseline hypoglycaemic clamp study also 
consented to an end of study clamp.  Three of these participants reported an 
improvement in hypoglycaemia awareness, with an improvement in Gold score to 
less than four, and were defined as responders to treatment.  The remaining two 
participants did not improve their Gold score, which remained above four, and 
were defined as non-responders to treatment.   
 
Figure twenty shows the changes in mean symptom scores and mean heart rate 
responses to hypoglycaemia in the responder group.  In the end of study clamp, 
symptom scores increased, at the onset on hypoglycaemia (T100) but were lower 
than in the baseline clamps towards the end of the studies.  Participants reported 
increases in both autonomic and neuroglycopenic symptoms but the glucose 
threshold for autonomic symptoms was still not reached in any of the three 
participants in the end of study clamp.  Threshold for total symptom scores 
showed little change from baseline clamps to the end of study clamps (2.73 
mmol/l to 2.77 mmol/l).  Heart rate response to hypoglycaemia in the second 
clamp study showed a reduction in heart rate from the onset of hypoglycaemia to 
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Figure 20 Paired clamp results for responders. 
Despite reports of a lack of improvement of hypoglycaemia awareness in the non-
responder group, symptom scores in the clamp study did improve (figure 21).  
The first participant improved both autonomic and neuroglycopenic symptom 
awareness and increased glucose thresholds from 2.4 to 2.88mmol/l in total, 
autonomic and neuroglycopenic symptom scores.  The second participant 
improved neuroglycopenic scores (glucose threshold of 3.46mmol/l) but an 
improvement of autonomic symptoms was not seen.  Heart rate increased during 





















































Figure 21 Paired clamp results for non-responders. 
 
5.5 Conclusions 
This study recruited participants with T1DM and IAH, participants with T1DM 
and intact awareness of hypoglycaemia and participants without diabetes to act as 
a control group.  The participants with IAH had a longer duration of disease in 
comparison to those with intact symptomatic awareness of hypoglycaemia.  
Autonomic function testing showed that there was no evidence of clinically 
significant cardiac autonomic neuropathy in any participants, but resting heart rate 




















































July 2018 Page 106 
 
All participants underwent a hyperinsulinaemic hypoglycaemic clamp study.  
There was a reduction in symptom score and metanephrine response to 
hypoglycaemia in participants with IAH.  The heart rate responses to 
hypoglycaemia were time dependent and differed according to self reported 
awareness of hypoglycaemia.  There was some improvement in symptom scores 
in repeated clamp studies after a  six month treatment period of hypoglycaemia 
avoidance.   
 
IAH was associated with a long duration of disease.  Participants with IAH had a 
mean duration of disease of 31 years, in comparison to 21years, in participants 
with intact awareness.  This was despite attempting to match participants 
according to age and duration of disease.  This did not reach statistical 
significance which is most likely due to the small participant numbers in this 
study.  It does however support the conclusions summarised in chapter three, that 
participants with IAH had a significantly longer duration of disease compared to 
those with intact awareness. 
 
There was no evidence of clinically significant cardiac autonomic neuropathy on 
screening tests but baseline heart rate was higher in participants with diabetes.  
This study defined cardiac autonomic neuropathy as an abnormality in two or 
more cardiac reflex tests, as agreed and defined by the Diabetic Neuropathy Study 
Group in Toronto, Canada in 2009 (Tesfaye et al., 2010).  Screening autonomic 
function tests revealed that no participants in any of the three groups met these 
criteria.  However, baseline heart rate (T20) was higher in the participants with 
IAH (79bpm), in comparison to participants with intact awareness (72bpm) and 
those without diabetes (65bpm).  This corresponded to a reduction in Log HF or 
vagal tone of 1.7 in participants with IAH in comparison to 2.1 in participants 
with intact awareness and 2.6 in those without diabetes.   
IAH was associated with reduced symptom scores and metanephrine responses to 
hypoglycaemia.  Although glucose thresholds for symptom score and 
metanephrine release appeared similar between the groups these thresholds were 
not reached in sixty three percent of the participants with IAH.  This is most likely 
due to the level of hypoglycaemia.  The final glucose step was 2.4mmol/l which 
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was probably not low enough to precipitate a full autonomic response in the 
participants with IAH.  The threshold for total symptom scores reduced in the 
participants that reported improved symptomatic awareness of hypoglycaemia 
after involvement in the hypoCOMPaSS trial.  However the threshold for 
autonomic symptoms was still not met in any of these participants. 
Heart rate response to hypoglycaemia was time dependent and differed according 
to self reported awareness of hypoglycaemia.  Participants without diabetes 
showed a transient increase in heart rate with recovery to baseline, caused by 
transient vagal withdrawal illustrated by a reduction in high frequency power.  
Participants with T1DM and intact awareness of hypoglycaemia showed an 
increase in heart rate caused by a withdrawal in vagal tone, which did not show 
evidence of recovery during the clamp studies.  The participants with IAH showed 
little changes in heart rate with minimal reductions in both vagal and sympathetic 
tone. 
The association of a long duration of diabetes and a reduction in awareness of 
hypoglycaemia is fairly well documented (Hepburn et al., 1990, Mokan et al., 
1994).   Impaired adrenergic and symptomatic responses to hypoglycaemia are 
common in patients with T1DM with established disease, even in those who claim 
to have normal awareness of hypoglycaemia (Heller et al., 1987).  More recently a 
study by Geddes and colleagues have confirmed that patients with IAH have a 
significantly longer duration of disease (Geddes et al., 2007). 
The participants in this study did not have clinically significant cardiac autonomic 
neuropathy.  The prevalence of DAN in T1DM depends upon the population 
studied and the criteria used to identify cardiac autonomic neuropathy (Pop-Busui, 
2010).  The prevalence of cardiac autonomic neuropathy reported in the 
Epidemiology of Diabetes Interventions and Complications (EDIC) study, with 
participants with duration of diabetes greater than 15 years, was 31%.  In these 
studies cardiac autonomic neuropathy was evaluated by heart rate variability 
during deep breathing and the valsalva manoeuvre and diastolic blood pressure on 
standing.  Cardiac autonomic neuropathy was defined as an abnormality in any 
one of these tests which significantly differs from the more recent guidance 
(Tesfaye et al., 2010) requiring an abnormality in two or more cardiac reflex tests.  
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However, if the EDIC criteria were applied to our study population only one 
participant would be diagnosed with DAN. 
 
The low prevalence of cardiac autonomic neuropathy in our study population may 
be due to bias introduced by the exclusion criteria of the clamp studies.  These 
excluded participants with ischaemic heart disease, peripheral vascular disease 
and nephropathy.  Microvascular complications such as nephropathy are 
associated with DAN as are cardiovascular risk factors such as hypertension and 
high risk lipid profiles (Vinik et al., 2003).  The exclusion criteria were included 
to ensure safety during the clamp studies but will have caused a selection bias. 
 
Although participants did not fulfil the criteria for definitive cardiac autonomic 
neuropathy, resting heart rate in participants with diabetes was higher than those 
participants without diabetes.  Ewing, Campbell and Clarke (Ewing et al., 1981) 
reported that patients with diabetes and parasympathetic abnormalities had higher 
heart rates in 1981.  More recently resting tachycardia (Vinik and Ziegler, 2007, 
Maser and Lenhard, 2005) as a result of vagal neuropathy has been described as a 
clinical implication of cardiac autonomic neuropathy.  
 
The reduction in hypoglycaemic symptoms and catecholamine responses to 
hypoglycaemia in patients with diabetes with impaired and intact awareness is 
well established (Heller et al., 1987, Amiel et al., 1988).  More recently Olsen and 
colleagues (Olsen et al., 2014) examined the effect of duration of diabetes upon 
symptomatic awareness of hypoglycaemia.  Questionnaires were sent to 636 
patients with T1DM and researchers found that a long duration of disease was 
associated with a lower intensity of autonomic symptoms.   
 
Previous experimental work has been done to assess the effect of  hypoglycaemia 
on cardiac autonomic function but results have been inconsistent and 
contradictory (Laitinen et al., 2003, Schachinger et al., 2004, Koivikko et al., 
2005, Chow et al., 2017).  Our results are consistent with Koivikko et al 
(Koivikko et al., 2005) who reported HRV responses to hypoglycaemia in people 
with and without diabetes undergoing a hyperinsulinaemic hypoglycaemic clamp 
study.  Average baseline heart rate was higher in participants with diabetes 
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(72bpm) in comparison to participants without diabetes (59bpm).  The authors 
reported an increase in heart rate and a decrease in HF power during 
hypoglycaemia, indicating vagal withdrawal.  Koivikko et al did not report 
evidence of recovery but the results in this study were reported at a single time 
point and we have shown that responses seen in cardiac autonomic function are 
time dependent.   
 
The differences seen in the work by Laitinen and colleagues (Laitinen et al., 2003) 
and the Schachinger group (Schachinger et al., 2004) are also possibly due to 
reporting results at a single time point.  Both studies recruited participants without 
diabetes and heart rate and HRV measures were recorded in euglycaemic and 
hypoglycaemic clamp studies.  They reported heart rate and HRV measures at a 
single time point.   Schachinger et al made these measures at 65 minutes 
following achievement of hypoglycaemia (glucose 2.7mmol/l).  Participants in 
our study had shown recovery at this time with heart rate returning back to 
baseline.  
 
Our results indicate that duration of diabetes is a major influencing factor in both 
symptomatic awareness of hypoglycaemia and cardiac autonomic function.  The 
relationship between subclinical and clinical autonomic neuropathy is potentially 
similar to that observed in diabetic peripheral neuropathy.  Diabetic peripheral 
neuropathy affects fifty percent of patients with diabetes, with abnormalities in 
nerve conduction tests, but clinical symptoms are only present in a third of 
patients (Tesfaye and Selvarajah, 2012).  Diabetic peripheral neuropathy is also 
associated with a long duration of disease.  We hypothesise that the increase in 
heart rate that is seen in the participants with diabetes at baseline, is most likely 
due to subclinical autonomic neuropathy, which is more pronounced in 
participants with IAH because of a longer duration of disease.         
 
The presence of subclinical cardiac autonomic neuropathy, in participants with 
diabetes and a long duration of disease, has potential clinical implications because 
of previous reports of the cardioprotective role of vagal activity.  The majority of 
this work has been observed in patients following an acute myocardial infarction.  
Initially animal studies indicated that increased vagal tone following myocardial 
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infarction gave protection from ventricular fibrillation (Schwartz et al., 1984, Hull 
et al., 1990).  Studies in humans followed showing that  reduced HRV was a 
predictor of increased mortality following acute myocardial infarction (Kleiger et 
al., 1987, Bigger et al., 1992).           
 
Limitations 
This is experimental work and therefore caution should be applied when 
extrapolating the results to the clinical scenario of spontaneous hypoglycaemia.  
Experimental work investigating the changes in cardiac repolarisation in 
hypoglycaemia showed a shortening of QT interval caused by adrenergic 
stimulation (Robinson et al., 2003b).  A follow up study by the same group 
showed these observed changes were less in spontaneous hypoglycaemia which 
was thought to reflect the reduced sympathoadrenal responses in this clinical 
scenario (Robinson et al., 2004).     
 
Limitations of this study include the use of spontaneous breathing during cardiac 
autonomic function testing, and the use of two rather than three questionnaires 
and catecholamine results at baseline to calculate glucose thresholds for 
symptoms and sympathoadrenal responses respectively.  Paced breathing is 
recommended for the interpretation of HF power (Tesfaye et al., 2010) because 
HRV is affected by the respiratory rate and depth of breathing.  During the clamp 
studies participants were instructed to breathe spontaneously during ECG 
recordings rather than to pace their breathing at a particular rate.  This was 
because of the concern about cognitive impairment during hypoglycaemia which 
could potentially impair the ability of the participants to pace their breathing 
consistently.  Ideally three questionnaires and three blood samples for 
metanephrines would have been used to calculate thresholds for participants.  It 
was felt that this was too cumbersome in these studies and therefore two baseline 
samples were used instead.   
Plasma metanephrine were used as a measurement of sympathoadrenal response 
to hypoglycaemia rather than adrenaline.  This was chosen for logistical reasons 
in the main hypoCOMPaSS trial and was therefore also used in the sub-study to 
allow a direct comparison of results.  Although studies (Lee et al., 2011, Whiting 
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and Doogue, 2009) have shown plasma metanephrine to be as effective as plasma 
catecholamines in measuring adrenal response, previous hypoglycaemic clamp 
studies (Koivikko et al., 2005, Laitinen et al., 2003) have traditionally used 
adrenaline.  This makes it more difficult to directly compare our results to 
previously published work.   
Summary 
In summary participants with T1DM had evidence of subclinical cardiac 
autonomic dysfunction which is associated with a long duration of disease.  
Baseline heart rate was elevated in participants with diabetes compared to 
participants without diabetes and this was associated with reduced high frequency 
power or vagal tone.  Baseline heart rate was highest in participants that reported 
IAH, who had a longer duration of disease, despite otherwise normal cardiac 
autonomic function testing.    
 
Cardiac autonomic responses to hypoglycaemia were time dependent and differed 
according to self reported awareness of hypoglycaemia.  Participants without 
diabetes showed a transient increase in heart rate associated with vagal 
withdrawal that recovered quickly.  Participants with diabetes and intact 
awareness of hypoglycaemia showed an increase in heart rate, associated with 
vagal withdrawal that did not show evidence of recovery during the clamp study.   
 
Participants with IAH showed little change in heart rate or HRV during 
hypoglycaemia.  This could be due to either true autonomic dysfunction or a 
failure of autonomic responses to hypoglycaemia.  We suspect that the second 
hypotheses is more likely and associated with both a long duration of disease and 
reduced autonomic responses following repeated episodes of hypoglycaemia.    
 
Future work could explore these findings further by repeating the studies with 
larger patient groups.  A longer period of hypoglycaemia would establish if those 
participants with intact awareness of hypoglycaemia would show evidence of 
recovery as illustrated by participants without diabetes.  Studies investigating 
cardiac autonomic responses during spontaneous hypoglycaemia would give more 
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information about cardiac autonomic function when the length and depth of 
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Chapter 6: Conclusions 
 
The three studies described in this thesis examine the relationships between IAH 
and DAN in T1DM. The first study compared the prevalence of DAN in 
participants with T1DM and IAH against participants with TIDM and intact 
symptomatic awareness of hypoglycaemia. The second study explored the 
question of whether the presence of DAN impaired the patient’s ability to respond 
to treatment for IAH. The final study investigated cardiac autonomic responses to 
experimental hypoglycaemia. 
The first study concluded that cardiac autonomic neuropathy was not associated 
with IAH. The prevalence of cardiac autonomic neuropathy in long standing 
T1DM was surprisingly low. The results also indicated that the severity of 
autonomic neuropathy increased with an increased duration of disease.  
 
The second study concluded that the presence of DAN did not impede the ability 
of participants to improve their symptomatic awareness of hypoglycaemia. It also 
found that IAH was associated with a longer duration of disease and an increased 
prevalence of SH. Younger participants and those with a shorter duration of 
disease showed greater improvements in symptomatic awareness than older 
participants with a longer duration of disease. 
 
The third study concluded that heart rate response to hypoglycaemia was time 
dependent and differed according to self reported awareness of hypoglycaemia. 
Participants with diabetes had a higher resting heart rate compared to participants 
without diabetes.  During the hypoglycaemic clamp studies participants with IAH 
had reduced symptomatic and metanephrine response to hypoglycaemia than 
those with reported normal awareness.  
 
In the remainder of this chapter, Sections 6.1 – 6.4 explore these key findings in 
more depth, and relate them to previous studies.  Section 6.5 considers their 
clinical implications.  Section 6.6 discusses the limitations of our experimental 
settings.  Finally Section 6.7 offers final conclusions and discusses future work. 
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6.2 The Low Prevalence of Diabetic Autonomic Neuropathy 
The prevalence of cardiac autonomic neuropathy was low in the participants 
enrolled in these studies with only seven of the 144 (5%) patients having definite 
cardiac autonomic neuropathy.  This is low when compared to other studies. In 
the DCCT (Pop-Busui et al., 2016), patients with T1DM of duration of 1-15 years, 
the prevalence of DAN was 9% which rose to 31% in the EDIC (Group, 2005) 
studying participants with a duration of diabetes greater than 15 years.  A study by 
Ziegler et al (Ziegler et al., 1992) in 1992 reported a prevalence of cardiac 
autonomic neuropathy in almost seventeen percent of participants with T1DM.  A 
French study published in 2003 (Valensi et al., 2003) report the prevalence of 
moderate or severe cardiac autonomic neuropathy in T1DM, defined as an 
abnormality in two or more tests, as eighteen percent. 
 
One reason for this disparity is due to differences in the way that DAN is defined.  
This is corroborated by a report by Vinik et al. (Vinik et al., 2003), who found that 
the prevalence of DAN ranges between 0 and 90% depending upon the study 
population and diagnostic criteria.  In our studies definite cardiac autonomic 
neuropathy was defined as the presence of two or more abnormal cardiac reflex 
tests (Tesfaye et al., 2010) following the 2010 Toronto consensus statement 
released by the Diabetic Neuropathy Study Group of the European Association for 
the Study of Diabetes.  O’Brien (O'Brien et al., 1986) stated in 1986 that 
autonomic neuropathy should not be diagnosed on the basis of one abnormal 
cardiac reflex test as thirteen percent of a healthy population without diabetes had 
an inadequate heart rate response to one of four reflex tests in a study in 1986.  
Less than two percent of participants had an abnormality in two or more tests. 
 
 In the DCCT and EDIC studies cardiac autonomic neuropathy was defined as an 
abnormality in any one of three cardiac reflex tests.  Applying the same diagnostic 
criteria to participants in this study 24% of participants would be classified as 
having cardiac autonomic neuropathy.  The DCCT and EDIC did not use age-
related normal ranges for the cardiac reflex tests which were used in this study 
which may account for the reduction in prevalence of DAN in the subjects in the 
hypoCOMPaSS studies. 
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Another reason could be the fact that improved treatment has led to a reduction in 
the prevalence of complications.  Intensive insulin therapy has led to significant 
improvements in glycaemic control.  Other microvascular complications of 
diabetes, specifically nephropathy, have significantly declined over the past thirty 
years with a reduction from thirty two percent to eleven percent (Nordwall et al., 
20014).   
 
6.3 Cardiac Autonomic Neuropathy is not Associated with 
Impaired Awareness of Hypoglycaemia 
The clinical syndrome of IAH was not associated with the presence or absence of 
DAN.  Seventy one percent of participants with normal awareness of 
hypoglycaemia had completely normal cardiac autonomic function tests in 
comparison to eighty percent of the participants with IAH.  Historically DAN was 
described as the mechanism causing IAH, but the data in the literature is 
conflicting (Stephenson et al., 1996, Meyer et al., 1998, Ryder et al., 1990, 
Hepburn et al., 1990).  Our findings tally with the findings of a recent study by 
Olsen and colleagues (Olsen et al., 2016), who also concluded that IAH was not 
associated with autonomic neuropathy. 
 
The aforementioned studies were also inconclusive on the question of whether 
DAN can affect the ability of participants to improve their awareness of 
hypoglycaemia. In our study DAN did not affect this ability.  The hypoCOMPaSS 
trial showed that improvement of hypoglycaemia awareness with a reduction of 
SH was possible in longstanding T1DM (Little et al., 2014).  Participants had a 
mean reduction in Gold score from five to four and average episodes of SH 
reduced from four to zero with the percentage of participants affected reducing 
from 92% to 6%.   
 
When comparing the improvement in IAH, there was no difference in mean 
reduction of Gold score in participants with definite DAN and those with normal 
cardiac autonomic function tests.  Both groups reduced their Gold score by 1.2.  
These results corroborate the findings of a recent study by Kamel et al (Kamel et 
al., 2015), who showed that reversal of hypoglycaemia unawareness following 
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islet cell/pancreatic transplant was not hampered by the presence of autonomic 
neuropathy. 
 
IAH was associated with an increased incidence of episodes of SH.  Participants 
that reported intact awareness of hypoglycaemia reported an absence of episodes 
of SH in the twelve months preceding the study.  Participants reporting IAH 
described a median incidence of SH of four in the same time period.  The 
relationship between IAH and SH is well established and was described by Gold 
et al (Gold et al., 1994).  They reported an average annual incidence of severe 
hypoglycaemia of 2.8 in participants with IAH compared to 0.5 episodes per year 
in patients with normal symptomatic responses to hypoglycaemia.  
6.4 Cardiac Autonomic Regulation during Experimental 
Hypoglycaemia 
During the hypoglycaemic clamp studies there was a reduction in symptomatic 
and metanephrine response to hypoglycaemia in participants with IAH.  Plasma 
metanephrines and reported symptoms increased in all three participant groups but 
autonomic symptom score and metanphrine thresholds were not reached in 63% 
of participants with IAH.  Participants with diabetes reported normal awareness of 
hypoglycaemia also showed reduced symptomatic and metanephrine response to 
hypoglycaemia in comparison to the group without diabetes.  Glucose thresholds 
for metanpehrine response were 2.92 mmol/l in the group with diabetes versus 
3.29 mmol/l in control group.  This reduction in symptom and sympathoadrenal 
response is established and have been reported previously (Heller et al., 1987, 
Amiel et al., 1988). 
 
Resting heart rate in participants with diabetes was higher than those without 
diabetes indicating an element of cardiac autonomic dysfunction.  Baseline 
cardiac autonomic function testing was normal in all participants undergoing a 
clamp study but baseline heart rate was higher in the participants with IAH 
(79bpm), in comparison to participants with intact awareness (72bpm) and those 
without diabetes (65bpm).  This corresponded to a reduction in high frequency 
(HF) power or vagal tone of 1.7 in participants with IAH in comparison to 2.1 in 
participants with intact awareness and 2.6 in those without diabetes.  Studies have 
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consistently reported increased baseline heart rate in participants with diabetes 
(Ewing et al., 1981, Vinik and Ziegler, 2007, Maser and Lenhard, 2005, Koivikko 
et al., 2005) and vagal neuropathy has been described as a clinical implication of 
cardiac autonomic neuropathy (Vinik and Ziegler, 2007, Maser and Lenhard, 
2005). 
Heart rate response to hypoglycaemia was time dependent and differed according 
to self reported awareness of hypoglycaemia.  Participants without diabetes 
showed a transient increase in heart rate with recovery to baseline, caused by 
transient vagal withdrawal illustrated by a reduction in HF power.  Participants 
with T1DM and intact awareness of hypoglycaemia showed an increase in heart 
rate caused by a withdrawal in vagal tone, which did not show evidence of 
recovery during the clamp protocol.  The participants with IAH showed little 
changes in heart rate with minimal reductions in both vagal and sympathetic tone. 
Our group has previously reported heart rate response during hypoglycaemia in 
participants with and without T2DM (Chow et al., 2017) and the results were 
similar to those reported here.  Heart rate was higher in participants with diabetes 
(78bpm) in comparison to participants without diabetes (64bpm).  Both groups 
showed an increase in heart rate associated with a reduction in vagal tone during 
hypoglycaemia.  The participants with diabetes did show recovery of heart rate to 
baseline but this occurred later than in the participants without diabetes.  We 
suspect that if clamp studies reported here were longer we would have also seen 
recovery of heart rate and HRV measures.  The main difference between the 
participants with T1DM in our study and those in the T2DM study was duration 
of diabetes.  The participants in these studies with T1DM had a longer duration of 
diabetes in comparison to those in the T2DM study (21years versus 11 years 
respectively).   
 
6.5 Duration of Diabetes 
 
Our studies have shown that duration of diabetes is a major influencing factor of 
the development of IAH and DAN.  There was an increased prevalence of DAN  
and IAH in participants with a longer duration of disease.  Increased disease 
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duration was also associated with inability of participants to improve their 
awareness of hypoglycaemia. 
 
Although the prevalence of cardiac autonomic neuropathy was low in these 
studies there was an increase in prevalence as duration of diabetes increased.  All 
participants with duration of diabetes of less than 15 years had normal cardiac 
autonomic function.  Participants with duration of 15 to 30 years had a prevalence 
definite DAN of five percent compared to eight percent seen in those with 
duration of over 30 years.  Data from the DCCT and EDIC also show the increase 
in prevalence of DAN as duration of disease increases with a prevalence of nine 
percent in participants with disease duration of less than fifteen years and 31% in 
those with a duration of greater than fifteen years (Pop-Busui et al., 2016).  
 
IAH was associated with a longer duration of disease.  Despite attempting to 
match study populations for duration of disease participants with IAH had a mean 
duration of disease of 29 years in comparison to those with intact awareness of 22 
years (p<0.001).  The association of duration of disease and IAH has been 
previously reported (Hepburn et al., 1990, Mokan et al., 1994).  Hepburn et al 
described a group of patients reporting absent awareness of hypoglycaemia with 
only nineteen percent having duration of diabetes of less than fifteen years.    
 
There may be structural changes occurring to glucose sensing neurones that are 
associated with a long duration of disease, which are irreversible, similar to the 
irreversible changes seen in peripheral and autonomic neuropathy.  Glucose 
sensing neurones have been identified in the brain, intestine, hepatoportal vein 
and carotid body as well as pancreatic beta cells (McCrimmon, 2009).  Animal 
studies have shown that the detection of hypoglycaemia in the brain is essential.  
When precipitating peripheral hypoglycaemia, whilst maintaining brain 
normoglycaemia, counterregulatory responses are significantly reduced (Biggers 
et al., 1989).  Recurrent hypoglycaemia results in altered glucose sensing in the 
brain and mechanisms such as an increased ability to use glucose or an ability to 
use different fuels to maintain brain normoglycaemia have been suggested 
(McCrimmon, 2009). 
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Observation during the clamp studies showed that baseline heart rate was elevated 
in participants with IAH in comparison to participants with normal awareness of 
hypoglycaemia and this is most likely due to the differences seen in duration of 
disease.   This sub-study reported that participants with IAH had a mean duration 
of disease of 31 years, in comparison to 21 years in participants with intact 
awareness.  This increase in baseline heart rate is most likely due to subclinical 
cardiac autonomic neuropathy.   
 
We hypothesise that this subclinical autonomic neuropathy is more pronounced in 
participants with IAH because of a longer duration of disease. The relationship 
between subclinical and clinical autonomic neuropathy possibly follows a similar 
pattern to that of diabetic peripheral neuropathy.  Fifty percent of patients with 
diabetes have abnormal nerve conduction tests indicating the presence of 
peripheral neuropathy, however only a third of patients have any clinical 
symptoms (Tesfaye and Selvarajah, 2012).  
 
Duration of diabetes had a negative impact on the ability of participants to 
improve their awareness of hypoglycaemia.  Forty seven participants had duration 
of diabetes of less than 30 years and had a mean reduction in gold score of -1.3 
and participants with a duration of greater than 30 years had a mean reduction of -
0.9.  Similarly Fanelli et al (Fanelli et al., 1993b) found that participants with a 
longer duration of disease showed improvement in hypoglycaemia awareness but 
the recovery of responses was inversely correlated with duration of disease.   
 
Although both IAH and DAN were associated with a long duration of disease, the 
development of these clinical syndromes do not invariably affect patients who 
have had diabetes for a significant length of time.  We have shown in these studies 
that the prevalence of DAN can be low even in a group of patients with a long 
duration of disease.  And although the mean length of duration of diabetes was 
higher in the participants with IAH, five people in this group had a duration of 
diabetes of less than ten years, and thirteen participants in the normal awareness 
group had a duration of diabetes greater than thirty years.   
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6.6 Clinical Implications 
The confirmation that a long duration of disease is associated with IAH rather 
than DAN has important clinical implications.  The National Institute of Clinical 
Excellence (Guidance, 2015)  have recognised the importance of identifying 
patients with IAH and recommend assessing awareness of hypoglycaemia on an 
annual basis.  It is recognised that patients often underestimate the frequency of 
hypoglycaemia and under report impairment of warning symptoms (Heller et al., 
1995).  This increased risk in patients with a long duration of disease should be 
recognised and emphasised in clinical consultations. 
 
This work also confirmed that younger participants with a shorter duration of 
disease were more likely to improve their symptomatic awareness of 
hypoglycaemia than older patients with longer duration of disease.  Programmes 
with intensive support have been shown to improve hypoglycaemia awareness and 
reduce episodes of SH (Zoysa et al., 2013, Little et al., 2014).  Once IAH is 
identified patients should be referred urgently to specialised clinics to ensure the 
best outcomes.   
 
The presence of subclinical cardiac autonomic neuropathy, in participants with 
diabetes and a long duration of disease have potential clinical implications, 
because of the previous reports of the cardioprotective role of vagal activity 
(LaRovere et al., 1998).  Although caution should be applied when extrapolating 
the results of experimental work to the clinical scenario of spontaneous 
hypoglycaemia, the risk of prolonged vagal suppression should be considered.  
Cardiovascular health should be optimised in all patients with long standing 
T1DM.   
6.7 Limitations 
This study is limited by the number of participants recruited, but increasing 
participant numbers would be unlikely to change the conclusions made.  Power 
calculations were based on studies with a higher prevalence of DAN (Hepburn et 
al., 1990) and therefore the studies are underpowered.  However we have shown 
that the difference in the prevalence of definite cardiac autonomic neuropathy 
between participants with impaired and normal awareness of hypoglycaemia 
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differs only by one percent.  Therefore, increasing the number of participants is 
unlikely to change our conclusions that there is no association between IAH and 
DAN.      
 
There will be an element of selection bias in the recruitment for these studies 
particularly elicited by the exclusion criteria of the clamp studies.  These excluded 
participants with ischaemic heart disease, peripheral vascular disease and 
nephropathy.  Microvascular complications such as nephropathy are associated 
with DAN as are cardiovascular risk factors such as hypertension and high risk 
lipid profiles (Vinik et al., 2003).  The exclusion criteria were included to ensure 
safety during the clamp studies but will have caused a selection bias. 
 
Spontaneous breathing was used in comparison to paced breathing during ECG 
recordings.  Paced breathing is recommended for the interpretation of HF power 
(Tesfaye et al., 2010).  HRV is affected by the respiratory rate and depth of 
breathing.  As participants were being investigated by different clinical teams in 
different parts of the country it was felt that spontaneous breathing would limit 
inter-investigator differences.  During the clamp studies participants were 
instructed to breathe spontaneously during ECG recording rather than to pace 
their breathing at a particular rate.  This was because of the concern about 
cognitive impairment during hypoglycaemia which could potentially impair the 
ability of the participants to pace their breathing consistently.  All participants had 
their respiratory rate measured to ensure that this was not fewer than 10 breaths 
per minute.   
 
Further consideration should be given to other measures of autonomic 
dysfunction.  This study used cardiac reflex tests to assess autonomic function and 
did not utilise other tests of the autonomic nervous system including tests of 
pupillomotor or sudomotor function.  Tests for cardiac autonomic function are 
simple, quick, non-invasive and can be done at the bedside.  Testing was limited 
to these tests to allow the tests to be done in each centre and then analysed in one 
site to improve reliability.    
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A specific limitation during the clamp studies was the use of two questionnaires 
and metanephrine results at baseline to calculate thresholds .  Ideally three 
questionnaires and three blood samples for metanephrines would have been used 
to calculate thresholds for participants.  It was felt that this was too cumbersome 
in these studies and therefore two baseline samples were used instead.   
6.8 Future Work 
 
We did not collect information about the prevalence of mild hypoglycaemia and 
the onset of episodes of SH in relation to symptomatic awareness and this would 
be an interesting focus to explore further during future work.  Continuous glucose 
monitoring is now used frequently clinically and would be a viable tool to collect 
this information.  The development of clinically relevant IAH is reported to be  
about twenty percent (Geddes et al., 2008), but the mechanism for developing 
IAH is still not clear.  Recurrent and frequent exposure to hypoglycaemia has 
been suggested as possible cause (Frier et al., 2014) with the mechanism 
suggested as the increase in glucose threshold (a lower blood glucose is required 
to initiate a counterregulatory response) caused by protracted hypoglycaemia 
(Boyle et al., 1988).  When this occurs neuroglycopenic symptoms can occur 
before autonomic responses are elicited (Hepburn et al., 1991).  
 
Further large epidemiological studies are required to document an accurate 
prevalence of DAN using the new definitions of cardiac autonomic neuropathy 
(Tesfaye et al., 2010) and association with other complications of diabetes.  The 
prevalence of DAN reported here was low potentially due to the characteristics of 
this particular study population that had a low prevalence of diabetic nephropathy.  
DAN is an important complication of diabetes because of the increased risk of 
death but it is one of the least studied.  
 
The natural history of DAN should be documented particularly focusing on the 
potential progressive nature of the condition.  There would be difficulties in 
recruiting participants for these studies.  The study would be screening for a 
condition that has no treatment and a poor prognosis with no personal advantages 
for participants.  Participants with severe cardiac autonomic neuropathy are likely 
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to be symptomatic and have other complications of diabetes making attendance 
for study visits difficult.  The studies would potentially need to continue for 
decades to document any progression or new onset of neuropathy.         
 
It would be interesting to repeat the hypoglycaemic clamp studies with an 
extended period of hypoglycaemia to observe whether there was cardiovascular 
recovery in patients with diabetes.  Recovery of heart rate and vagal withdrawal 
was observed in participants without diabetes but this was not seen in participants 
with diabetes. However, recruiting participants for clamp studies is challenging 
because of the cumbersome nature of the protocols.  A longer period of 
hypoglycaemia may prevent participants consenting to these studies.   
 
Participants with IAH showed little change in heart rate and associated vagal and 
sympathetic tone during hypoglycaemia.  We would hypothesise that this is due to 
a higher glucose threshold and if blood glucose was lowered further than this 
clamp study allowed then an autonomic response would eventually be seen with 
the corresponding cardiovascular changes seen in the control populations.  This 
level of hypoglycaemia would potentially cause harm to participants and therefore 
remains a hypothesis currently.  Spontaneous hypoglycaemia may be at this level 
for a significant amount of time in patients with IAH without their knowledge due 
to a lack of warning symptoms.  This could be measured by blinded CGM while a 
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Appendix 1: ADA/WHO Definition of T1DM 
 
1. Fasting plasma glucose ≥ 7.0 mmol/l. Fasting is defined as no caloric intake for 
at least 8 h. 
OR 
2. Symptoms of hyperglycaemia and a casual plasma glucose ≥11.1 mmol/l. 
Casual is defined as any time of day without regard to time since last meal. The 
classic symptoms of hyperglycaemia include polyuria, polydipsia, and 
unexplained weight loss. 
OR 
3. 2-h plasma glucose ≥ 11.1 mmol/l during an OGTT. The test should be 
performed as described by the World Health Organization, using a glucose load 
containing the equivalent of 75 g anhydrous glucose dissolved in water.  
In the absence of unequivocal hyperglycaemia, these criteria should be confirmed 
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Appendix 2: Gold Score 
 
The Gold Score 
 
Do you know when your hypos are commencing?  Please circle a number: 
 
         Always aware                       Never aware 
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Appendix 3: Hypoglycaemic Questionnaire 
Hypoglycaemic Questionnaire 
Date:     Time:      
Initials:   
ON A SCALE OF 1 (NOT AT ALL) TO 7 (VERY SEVERE), CIRCLE THE NUMBER THAT YOU THINK 
BEST DESCRIBES YOUR AWARENESS OF EACH SYMPTOM. 
 
                                     NOT AT ALL      VERY SEVERE 
 
ODD BEHAVIOUR  1 2 3 4 5 6 7  
 
POUNDING HEART 1 2 3 4 5 6 7  
 
ITCHING   1 2 3 4 5 6 7  
DROWSINESS  1 2 3 4 5 6 7 
 
DIFFICULTY  1 2 3 4 5 6 7  
SPEAKING          
 
SHAKING/TREMOR 1 2 3 4 5 6 7  
 
HEADACHE  1 2 3 4 5 6 7  
 
HUNGER  1 2 3 4 5 6 7  
 
CLUMSINESS/  1 2 3 4 5 6 7  
INCOORDINATION         
 
SWEATING  1 2 3 4 5 6 7  
 
CONFUSION  1 2 3 4 5 6 7  
 
NAUSEA   1 2 3 4 5 6 7  
 
DIZZINESS  1 2 3 4 5 6 7  
 
BLURRED VISION  1 2 3 4 5 6 7  
 
ANXIETY   1 2 3 4 5 6 7  
 
WEAKNESS  1 2 3 4 5 6 7  
 
TINGLING  1 2 3 4 5 6 7   
 
WARMTH  1 2 3 4 5 6 7  
 
IRRITABILITY  1 2 3 4 5 6 7  
DO YOU FEEL AS THOUGH YOUR BLOOD GLUCOSE LEVEL IS LOW? YES  ___ NO ____ 
Please tick ( appropriate box 
What do you think your glucose level is?___________mmol/l 
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